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The mechanism of disease onset for chronic kidney disease (CKD) is not fully understood. A 
rise in CKD rates has occurred concomitant with the rise in prevalence of obesity. We 
hypothesized that renal lipid accumulation, which occurs in obesity, is an early mediator of 
kidney dysfunction, and that it may drive pathological changes associated with CKD, including 
increased incidence of diabetes and CVD. To elucidate a possible role for lipid accumulation in 
kidney dysfunction and associated co-morbidities, a renal-tubule-specific model is required that 
is not confounded by the plethora of systemic metabolic changes that can occur in obesity. To 
develop this, I first characterized renal lipolysis to identify promising target proteins. I found 
that total [3H] triolein hydrolase activity of kidney lysates was significantly increased by 15% in 
the fasted state, and that adipose triglyceride lipase (Atgl) and hormone-sensitive lipase (Hsl) 
mRNA expression were time-dependently increased by fasting, along with other fatty acid 
metabolism genes (Ppar, Cd36, and Aox). ATGL and HSL protein levels were also significantly 
induced (by 2397% and 3228%, respectively) 16 h after food withdrawal. Concomitant with 
changes in total protein levels, there was an increase in ATGL phosphorylation at the AMPK-
regulated serine 406 site in the 14-3-3 binding motif, and an increase in HSL phosphorylation at 
serine 565 and 660 that are regulated by AMPK and PKA, respectively. Using 
immunofluorescence, I further demonstrated nearly ubiquitous expression of ATGL in the renal 
cortex, with a concentration on the apical/lumenal surface of some cortical tubules.  
My findings suggested that ATGL-mediated lipolysis may be a suitable process to target to 
generate a model for elucidation of the role of lipid accumulation in kidney dysfunction. In this 
regard, I used transgenic mice expressing Cre recombinase under control of a renal-tubule-
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specific promoter, and mated them with mice that harbour LoxP sites in the regions flanking 
the first exon of ATGL, in order to make renal-tubule-specific ATGL knockout mice (KSAKO). All 
studies reported utilized male mice only. Male KSAKO mice gained weight faster than wildtype 
mice. However, at 20 weeks, body weights were not significantly different. We found an 
increase in kidney and liver weights in KSAKO mice, and decreases in adipose tissue depot 
masses at 20 weeks of age. ATGL mRNA and protein were reduced in whole kidneys of KSAKO 
mice by 25% and 33%, respectively. There was a compensatory 74% increase in Hsl mRNA at 20 
weeks of age in male KSAKO mice. Specificity of ATGL knockout was confirmed by 
immunoblotting for ATGL in heart and adipose tissue of KSAKO mice, where ATGL was not 
reduced compared to wildtype. In fact, ATGL was induced in peri-renal WAT by 248%, which 
may help to explain the significantly reduced tissue mass. Glucose tolerance and insulin 
sensitivity were tested. KSAKO mice were initially found to be more insulin sensitive at 9 weeks 
of age, but then more insulin resistant at 16 weeks of age. Impaired insulin sensitivity and 
glucose tolerance in adult mice occurred concomitant with increased renal mRNA expression of 
markers of inflammation and fibrosis, including Il-6 (312% increase) and fibronectin (38% 
increase). The ablation of renal Atgl also resulted in an increase in plasma triacylglycerol (TAG) 
levels, although this did not reach significance with the number tested. Taken together, my 
findings indicate an important role for renal lipolysis in the mediation of whole body glucose 
and TAG metabolism. Further study will be required to elucidate the mechanism(s) underlying 
the disruption to glucose handling in KSAKO mice. These findings will be important for 
understanding the pathobiology of kidney disease, and the role of kidney lipid metabolism in 
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1 in 10 North Americans has chronic kidney disease (CKD) and millions more are at risk (2,3). 
This life threatening disease causes kidney function to deteriorate, creating a condition where 
kidneys can no longer sufficiently filter the blood. CKD leaves the patient with a severely 
reduced quality of life and when left untreated will succumb to the disease. CKD is 
characterized by a reduction in kidney function over several months and is diagnosed by a 
glomerular filtration rate (GFR) less than 60 ml/min/1.73m2 for at least 3 months (4). With a 
continued loss of GFR, patients are dependent on routine dialysis to artificially filter their blood, 
costing $49 billion annually in the US alone (5). Even with life supporting dialysis, the probability 
of surviving the first five years with kidney failure is only 35 percent (3). Despite the enormity of 
the problem, there are currently no therapeutic strategies to directly prevent or treat CKD, and 
mechanisms mediating the onset of CKD are poorly understood.  
The progressive rise in CKD rates in Canada over the last 50 years can be linked in part to an 
aging population, since incidence of CKD is dramatically higher in individuals over 65 yrs (3). 
However, the rate of increase in incidence of CKD has stabilized in recent years, even though 
the demographic continues to age, suggesting that other factors are also involved. In this 
regard, obesity is another major risk factor for CKD, and the rise in obesity in recent decades 
has been closely paralleled by increases in CKD incidence (Figure 1). 
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Figure 1: The relationship between obesity prevalence and CKD incidence. 
Data adapted from (3,6) 
 
Much of this link has been causally attributed to the accompanying rise in obesity-related 
conditions such as hypertension and hyperglycemia, since about 50% of dialysis patients have 
three or more comorbid conditions (7,8) that can damage glomeruli. However, obesity remains 
a risk factor for End-Stage Renal Disease (ESRD), or renal failure, even after adjustment for 
confounding co-morbidities such as diabetes and hypertension (9), indicating that other 
obesity-related factors must play a role in damaging the kidneys. In addition, while it is well 
established that renal disease can be caused by pre-existing metabolic conditions, the reverse 
also appears to be true.  Renal disease increases the risk of developing new-onset metabolic 
syndrome (10), diabetes mellitus (11) and cardiovascular disease (12). Awareness of this 
appears to be growing. For example, the term “renocardiac syndrome” was recently coined (13) 
to describe the initiation of cardiovascular disease following kidney damage, although the term 
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“cardiorenal syndrome”, denoting the development of kidney disease in patients with heart 
disease, has been used for over 60 years. Despite this, relatively little mechanistic insight is 
available into the pathological factor(s) linking kidney disease to the initiation of other 
metabolic conditions. 
The mediators of renal injury in obesity are not fully identified, characterized, or 
understood. Although numerous metabolic changes occur in obesity (14), TAG overstorage both 
in adipose tissue, and ectopically in non-adipose tissues, is a hallmark of the dysregulated obese 
state (15). Most cells of the body are capable of storing intracellular TAG, at least to some 
extent (16). With rising levels of adiposity, lipid droplets of cellular TAG accumulate in non-
adipose tissues (17), and accumulation of renal TAG has been found to be associated with 
increasing BMI in humans (18). Lipid-mediated toxicity, or “lipotoxicity” is the term used to 
identify cellular damage and cell death caused by lipids. However, whether ectopic kidney lipid 
accumulation is merely a benign consequence of obesity, or whether it can initiate lipotoxicity, 
is currently unknown.  
In several forms of kidney injury, lipid droplets are reported to appear prior to infiltration by 
white blood cells, suggesting that they may actually cause damage (19). Mechanistically, it is 
highly likely that accumulation of lipids in the kidney leads to pathological changes. Lipid 
droplet accumulation and over storage in the kidney is associated with CKD and diabetes (20). 
Studies have demonstrated an association between obesity-induced and diabetes-induced lipid 
droplet accumulation in renal cells and renal pathology (21,22). Additionally, pathological 
changes have been found in kidneys of mice transgenic for sterol regulatory element-binding 
protein 1 (SREBP1) that causes renal lipid accumulation as a result of increased fat synthesis in 
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the kidney (23). However, results in all of these models are confounded by the lack of a kidney-
specific or renal tubule-specific approach. In obesity-induced or diabetes-induced models of 
renal lipid accumulation, metabolic, energetic, or hormonal changes in the blood and other 
tissues could influence events in the kidney, including the development of inflammation and 
the relative partitioning of fuel substrates. Likewise, in the SREBP1 transgenic model, 
overexpression of the transgene in liver and adipose tissue, in addition to kidney, may influence 
renal effects (23). Thus, whether accumulation of lipid in the kidney causes renal injury has not 
yet been investigated in a targeted and specific manner. 
Investigating the effects of isolated renal lipid accumulation on kidney health is important 
for understanding the pathology of obesity in CKD, and development of a targeted model would 
greatly facilitate this work. Additionally, development of a targeted model of renal TAG 
overstorage could shed new light on the relationship between kidney damage and the onset of 
CKD-associated co-morbidities. The cause of greater rates of development of new-onset 
diabetes mellitus in patients on renal dialysis is currently unknown (11). Additionally, while it is 
known that specific blood lipid abnormalities, particularly increases in plasma levels of TAGs 
and TAG-rich lipoproteins such as very low-density lipoproteins (VLDL), are often seen in CKD, 
the origins of these changes are not well understood (24). Thus, development of a model of 
renal tubule-specific TAG overstorage would allow for investigation not only of pathological 
changes occurring in the kidney, but also of potential mechanisms underlying whole-body 
metabolic disturbances in kidney disease.  
Achieving renal lipid accumulation (i.e. renal steatosis), in the absence of lipid accretion in 
other organs, requires a highly targeted approach that is not possible with diet or 
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pharmaceutical agents. Gene deletion or gene overexpression, targeted to renal tubules, could 
achieve a specific model of fat accumulation. There are many possible targets. The amount of 
TAG stored in a tissue is dependent on the balance between fat uptake, synthesis, and 
utilization, with different protein regulators acting at each step. Evidence suggests that 
targeting proteins involved in fat breakdown and utilization may be particularly effective. 
Lipolysis is the enzymatic process by which fatty acids are sequentially cleaved from the glycerol 
backbone of TAG. In white adipose tissue, the major storage site of TAG in mammals, the 
hydrolysis of TAG by lipolytic enzymes has been well characterized (16). Renal lipolysis has not 
yet been described, but evidence from gene knockout mice suggests that some of the principle 
protein regulators of adipocyte lipolysis may be functionally significant in kidney. In particular, 
mice that are totally deficient in adipose triglyceride lipase (ATGL), the enzyme that catalyzes 
the initial step in TAG hydrolysis, have a substantial accumulation of TAG in all tissues of the 
body, including kidney (25). Although broad changes in whole body lipid metabolism were 
evident in this non-targeted model, it does support a potential critical role for ATGL in renal 








To elucidate a role for renal lipolysis in the pathogenesis of kidney disease we must first 
understand the fundamentals of lipid breakdown in the body. The ability to switch between the 
fed and fasted state is a critical metabolic process, which enables a constant supply of energy 
substrates to meet the demands of all tissues. Instrumental to this switch is the ability to 
activate lipolysis. In this section we review the purpose of lipid mobilization during fasting and 
the key enzymes involved in initiating this process. We also review what is currently known 
about lipid handling in the kidney to form a foundation upon which to discuss the development 
and pathology of renal lipid accumulation. And, finally, we review the fundamentals of probing 
glycemia control, in order to help understand the role of renal lipid accumulation in the 
development of secondary co-morbidities such as insulin resistance. 
 
Lipid mobilization in fasting 
Higher eukaryotes have developed the ability to maintain the provisional release of 
nutrients, despite fluctuations in the external environment. Endogenous glycogen and lipid 
stores allow the body to maintain a constant supply of energy substrates irrespective of 
exogenous availability. The liver is the main provisional supplier of glucose for the body, storing 
it in response to elevated postprandial glucose levels and circulating insulin, and releasing it in 
response to a fall in blood glucose levels coupled with a rise in circulating levels of the 
hormones glucagon and norepinephrine (26). However, hepatic glycogen stores are limited to 
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~100 g (~400 kcal) in a typical adult (27), and are unable to supply adequate energy substrates 
alone for prolonged periods, even in individuals at rest. Additionally, it is metabolically critical 
that liver glycogen stores are conserved, because glucose-dependent tissues, such as the brain 
and red blood cells, cannot readily utilize other fuel sources. Lipid beta-oxidation is optimal for 
long term energy supply in part due to its caloric efficiency which yields about 9 kcal/g 
compared to 4 kcal/g for glucose. With fasting, a rise in glucagon and norepinephrine stimulates 
the hydrolysis of adipose tissue TAG resulting in a net increase in the release of free fatty acids 
(16). Most tissues are able to take up circulating free fatty acids (28). However, because excess 
free fatty acids are cytotoxic, they are typically stored upon uptake as TAG (29,30). In order to 
mobilize fatty acids for cellular uses including energy metabolism, free fatty acids must be 
hydrolyzed from TAG and released from the lipid droplet. This process is termed lipolysis. 
The regulated process of lipolysis contains three main enzymes, ATGL, hormone-
sensitive lipase (HSL) and monoglyceride lipase (MGL). These enzymes hydrolyze fatty acids 
from TAG in a step-wise manner. A summary of the characterization of these enzymes follows. 
 
Adipose Triglyceride Lipase 
Adipose triglyceride lipase, otherwise known as desnutrin or Pnpla2, belongs to the 
patatin domain-containing protein family that consists, in humans, of nine members. Discovery 
of ATGL was reported simultaneously in 2004 by three laboratories (31-33). It was selected as a 
candidate protein for study based on its differential expression in adipocytes compared to liver 
or skeletal muscle, and because it was structurally homologous to known lipases containing the 
GXSXG motif and alpha/beta (a/b) hydrolase folds that are characteristic of serine esterases. 
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The murine gene for ATGL encodes a 486 amino acid protein with a mass of 54 kDa (31). Atgl is 
found to be highly transcriptionally expressed in white and brown adipose tissues as well as 
cardiac muscle, skeletal muscle, testis and kidney (31), although protein expression in kidney 
has not yet been reported. White adipose tissue Atgl mRNA was also found to be under 
nutritional control, being induced with fasting (34). Evidence of ATGL TAG lipase activity comes 
from both in vitro and in vivo assays. The overexpression of ATGL in both HEK293 (31) and COS-
7 (32) cells results in a decrease in TAG and an increase in free-fatty acid release to the 
medium, with no change to phospholipids, and ATGL also does not express any activity for 
cholesteryl or retinyl-ester bonds (32,35).  Further evidence of the specific activity of ATGL is 
that TAG lipase activity is reduced by up to 60% in isolated Atgl knockout adipocytes (34), and 
TAG lipase activity is reduced by 70% when adipose tissue extract is treated with a polyclonal 
antibody against ATGL (32).   
The substrate and stereo-selectivity of ATGL in the catalytic release of free fatty acids 
from TAG is preferentially for the hydrolysis of long-chain fatty acid esters at the sn-2 position 
of the glycerol backbone generating sn-1,3 diacylglycerol (DAG), with little activity for the sn-1 
position (35).  However, in the presence of its co-activator CGI-58, ATGL also generates sn-2,3 
DAG, with similar preference for both sn-1 and sn-2 position (35). 
CGI-58 is a lipid-droplet associated protein that is widely reported to activate ATGL 
under conditions where lipolysis is stimulated, by facilitating translocation of ATGL from the 
cytosol to the lipid droplet (36,37). ATGL is also regulated by the activity of kinases, and is 
known to contain two serine residues that are subject to phosphorylation (34). In the mouse, 
these phosphorylation sites have been shown to be phosphorylated through the action of 
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AMPK (34,38). AMPK is a sensor for low energy states and is activated during fasting and 
exercise (39). However, the role of AMPK-mediated phosphorylation of ATGL in fasting induced 
lipolysis is not fully understood. 
The activation of ATGL initiates the rate limiting step of TAG breakdown, resulting in the 
release of fatty acids to match supply with demand. The diacylglycerol (DAG) product of TAG 
hydrolysis by ATGL continues through the lipolysis pathway. 
 
Hormone-Sensitive Lipase 
The second step in TAG catabolism involves HSL. HSL was discovered when it was found 
that hormonal stimulation induced lipolytic activity in adipose tissue (40,41). HSL contains a 
motif found in several lipases, the α/β hydrolase fold that is characterized by alternating alpha-
helices and beta-sheets, and that contains a catalytic triad of serine, aspartate or glutamate, 
and histidine (42). The serine residue at position 423 within the catalytic domain of HSL was 
found to be essential for hydrolase and esterase activity (43). After ATGL cleaves a fatty acid 
from TAG, a DAG is formed, which HSL hydrolyzes to release another acyl chain, forming 
monoacylglycerol. The HSL-catalyzed reaction favours the sn-1,3 DAG substrate, however, HSL 
will act on other species (35). The HSL enzyme also possesses TAG lipase activity, but its 
specificity for DAG is 10 times higher than that for TAG (35).  
The regulation of HSL involves both changes in phosphorylation state and co-enzyme 
activation. In the fasted state the catecholamine norepinephrine causes the activation of 
protein kinase A (PKA) through G-protein coupled cyclic-AMP (cAMP)-mediated signalling (44).  
A rise in cAMP concentrations results in increased binding of this nucleotide to the negative 
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regulatory subunit of PKA, resulting in release of the catalytic subunits that become active and 
phosphorylate HSL on multiple sites, including the activation sites Ser 653 (45), Ser659 (46) and 
Ser660 (46). PKA can also phosphorylate perilipins, a family of lipid droplet proteins, to increase 
HSL and ATGL recruitment to the lipid droplet (47). In the postprandial state, insulin exerts its 
anti-lipolytic effects, at least in part, through activation of phosphodiesterase 3B that degrades 
cAMP (16). A reduction in cAMP allows the regulatory subunits to sequester the catalytic 
subunits, reducing activation of PKA and stimulated lipolysis (16). This effect is enhanced by the 
activation of protein phosphatase-1 by insulin, which dephosphorylates HSL, causing its 
inactivation (48). HSL also contains a Serine 565 (S565) site (46), which has been shown to be 
phosphorylated by AMPK (49). The phosphorylation of S565 has been shown to inhibit HSL 
activity in WAT(50), however activation of lipolysis in muscle has been associated with 
increased S565 phosphorylation (51). Thus, whether AMPK activates or inhibits HSL is still 
unclear, and may be tissue specific.  
 
Monoglyceride lipase 
MGL is a 33 kDa hydrolase, first found in adipose tissue in 1971 (52), but subsequently found to 
be expressed relatively ubiquitously in all tissues. MGL is a specific monoacylglycerol hydrolase, 
acting at the last step of TAG breakdown on monoacylglycerols (MAG) at the 1-(3-) and 2- ester 
bonds at equal rates. MGL exhibits almost no activity for DAG, TAG, or cholesteryl ester 
substrates (53), and has activity with MAG that is 100 fold higher than the activity of HSL with 
DAG (54). This enzyme is therefore not rate limiting in the TAG hydrolysis pathway for fatty acid 
mobilization. Additionally, it is found in the cytoplasm rather than on the lipid droplet where 
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TAG is stored. For these reasons, we choose to focus on the effects of ATGL and HSL in the 
study of renal TAG lipolysis. 
 
Kidney lipid metabolism 
The majority of work on lipolysis has been performed in adipose tissue, while kidney 
lipolysis and renal lipid metabolism overall remains understudied. It is likely, however, that 
lipolysis is particularly important in the kidney. This organ is exposed to both circulating 
complex lipids and NEFA, as well as NEFA bound to albumin in the urinary filtrate, making it 
highly susceptible to the accumulation of TAG (55,56). Indeed, in the fasted state, circulating 
levels of adipose-derived NEFA rise, and the kidneys increase the uptake of NEFA from the 
plasma (57) and reuptake of albumin-bound fatty acids from glomerular filtrate  (55,56,58). The 
kidney also expresses several receptors for the uptake of lipids. Megalin, Cubilin and 
Amnionless are membrane proteins expressed along proximal tubules that are capable of 
interacting with lipid transport molecules including apolipoproteins and albumin (59) (and 
references therein). Renal tubule cells express receptors for the major classes of lipoproteins 
(60-62), as well as fatty acid transporters (17,63). And, the kidney can also take up TAG NEFA 
generated through lipoprotein lipase-mediated hydrolysis (64,65). Increases in the uptake of 
NEFA in fasting make it a major fuel source for the kidney, accounting for up to half of renal 
oxygen consumption in this state (66). 
Evidence indicates, however, that incoming FFA are not used directly, but first esterified 
into TAG (29,30). Lipolysis is therefore required to mobilize these stores for use (57,67). A 
critical role for ATGL in particular in this process is supported by studies in ATGL knockout mice 
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demonstrating significant TAG accumulation in the kidneys (25). Indeed, total deficiency of 
ATGL in mice has been shown to cause TAG accumulation in essentially all tissues analyzed, 
ultimately resulting in premature death due to contractile failure of TAG-suffused cardiac 
muscle. Although subsequent studies have examined effects of tissue-specific loss of ATGL in 
heart, liver, skeletal muscle, and brain, researchers have yet to investigate the role of ATGL in 
kidney, despite the fact that ATGL total null mice showed the second largest accumulation of 
TAG in this organ (an approximate 16-fold increase)(25). The finding of significantly elevated 
renal TAG in ATGL total-null mice provides strong evidence of an important role for ATGL in 
kidney. However, there are limitations to the direct interpretation of this finding. This model 
was a global ATGL knockout, and there were a host of significant changes including changes in 
adipocyte lipolysis and blood lipid and blood glucose levels that could indirectly affect kidney 
fat accumulation. It therefore cannot be conclusively determined from that model whether the 
renal lipid accumulation reported was due entirely to changes in renal lipolysis or whether 
other metabolic changes were the cause of TAG accumulation. In fact, very little is known about 
renal lipolysis, and it has not yet been reported whether ATGL protein is even found in kidney. 
 
Blood glucose clearance 
Insulin-independent effects 
 The concentration of blood glucose is tightly controlled, at around 5 mM. During fasting, 
blood glucose concentration remains constant, as a result of the balance between metabolic 
usage and hepatic glucose production. The liver is responsible during the post-absorptive state 
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for the majority of endogenous glucose production, while most glucose uptake occurs in 
insulin-insensitive (brain and splanchnic) tissues (68). Fasting blood glucose concentration is 
associated with plasma insulin level, because of the ability of this hormone to shut down 
hepatic glucose production. The uptake of glucose by tissues during the fasted state is largely 
mediated by the concentration gradient between the plasma and cytosol, which is termed 
glucose ‘mass action’. Only 25% of glucose uptake occurs in insulin-sensitive tissues, primarily 
skeletal muscle, during fasting conditions (68).  
 
Insulin-dependent effects 
In the absorptive state, the increase in blood glucose concentration stimulates the 
pancreas to release insulin.  When insulin is released into circulation, tissues sensitive to insulin, 
through insulin-receptors, are stimulated to recruit glucose transporters to allow glucose to 
enter the cell. Skeletal muscle, adipose tissue, and liver are responsible for the majority of 
blood glucose clearance resulting in a decrease in blood glucose concentrations.  Skeletal 
muscle is responsible for about 2/3 of post-prandial glucose clearance (69).  
Insulin also causes blood glucose concentration to decrease due to its effect on liver. 
Although the liver does not express insulin-regulated GLUT4 receptors for glucose uptake, the 
inhibition of hepatic glucose production contributes to the decrease in blood glucose 
concentration. 
Fasting glucose concentration is an indication of insulin sensitivity. Hepatic glucose 
production is the prominent supplier of blood glucose and this remains constant in the fasted 
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state. The inability of the liver to respond to insulin and decrease glucose production results in 
an elevated fasted blood glucose concentration, suggesting reduced insulin sensitivity. 
 
Physiological effects following intraperitoneal injection of glucose 
Glucose tolerance testing (GTT) assesses the ability of tissues to respond to a bolus of 
injected glucose, in order to clear glucose from the blood.  This ability is the result of combined 
effects of insulin secretion, insulin action and glucose ‘mass action’ (70). This test allows for the 
identification of disruptions to glucose metabolism that are associated with metabolic 
syndrome and diabetes. Animals are typically fasted overnight for 16 hours, baseline blood 
glucose concentrations are measured, and then an intraperitoneal (i.p.) injection of glucose is 
given (70). Injected glucose is absorbed into the blood stream from the peritoneal cavity, and 
blood glucose concentrations rise.  
The expected response is for the blood glucose concentration to rise rapidly, stimulating 
insulin release, and triggering an increase in insulin-mediated GLUT4-dependent glucose 
disposal, and inhibition of hepatic glucose production. After about 90 min, glucose 
concentration should be returned to baseline in animals with normal insulin sensitivity. 
Insulin resistance is the inability of tissues to respond appropriately to insulin. Insulin 
resistance would present as a greater increase in blood glucose concentration and slower 
return to baseline of blood glucose relative to control animals following i.p. glucose injection, 
due to blunted insulin-mediated glucose disposal and impaired suppression of hepatic glucose 
production. However, animals with a defect in insulin synthesis or release would have a 
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similarly impaired response to injected glucose. Thus, it is also necessary to directly examine 
the effect of insulin injection on dynamic blood glucose regulation. 
 
Physiological effects following intraperitoneal injection of insulin 
Insulin tolerance testing (ITT), also called insulin stress testing, assesses whole body insulin 
action (70).  Animals are fasted for a short period (5-6 h), and baseline blood concentrations are 
measured, and then an i.p. injection of insulin is given (70).  Insulin injection will stimulate 
insulin-mediated uptake of glucose as well as inhibit hepatic glucose production. 
The expected response is for blood glucose to decrease from a fasted level following insulin 
injection and to return to baseline about 60 min after injection. Insulin resistance will present 
as an attenuated decrease in blood glucose concentration following insulin injection, owing to 
reduced insulin action. However, if the insulin injection forces a decrease in blood glucose 
below 4.44 mM, the anti-insulin response from the adrenal system dominants (71) and may 
lead to confounding interpretations. Thus, insulin injections are only given to mice after a short 
(5-6 h) fast, rather than after a 16 h fast as is done in glucose tolerance testing. 
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CHAPTER 3- Fasting upregulates lipolysis in mouse kidney 
Results from this chapter have been published (1). 
Rationale 
Lipolysis is the enzymatic process by which fatty acids are sequentially cleaved from the 
glycerol backbone of TAG. In adipocytes, the major storage site of TAG in mammals, the release 
of NEFA by lipolytic enzymes has been well characterized (16). TAG is primarily hydrolyzed by 
ATGL to form DAG, which is subsequently hydrolyzed by HSL, although this enzyme has TAG 
hydrolase activity as well. These enzymes are expressed in other tissues including kidney 
(31,72), although not all reports agree (73), and the presence of ATGL protein in kidney has not 
yet been demonstrated. Thus, whether these enzymes are indeed present in kidney, and 
whether they are regulated to match changing requirements for lipolysis-derived substrates, 
remains to be fully characterized. This understanding has importance for renal health, given the 
role of fatty acids in renal energy metabolism and the detrimental consequences of renal 
steatosis (23).  
Objectives 
To characterize renal TAG lipolysis, in order to identify a suitable target enzyme for the 
generation of a model of renal tubule-specific lipid accumulation. 
Characterization will include investigation of: 
i. Renal TAG lipolysis activity in the fasted and non-fasted states 
ii. Expression, regulation and phosphorylation of lipolysis enzymes in kidney 
in the fasted and non-fasted states 
iii. Renal beta-oxidation capacity in the fasted and non-fasted states 
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iv. Kidney tissue localization of ATGL 
Hypotheses 
A 16 hour fast will: 
1. Induce TAG hydrolase activity in kidneys of mice 
2. Increase kidney ATGL and HSL mRNA expression and protein levels  
3. Increase the activating ATGL 14-3-3 binding domain sequence phosphorylation 
4. Increase the activating HSL S660 and S565 phosphorylations 
5. Increase activation of cAMP-activated protein kinase A (PKA) and 5’-adenosine 
monophosphate-activated protein kinase (AMPK) in kidneys 
6. Increase beta-oxidation in kidneys of mice 
7. Shift the respiratory exchange ratio towards 0.7 in mice, indicating greater lipid 
beta-oxidation 





Study design (feeding and timeline) 
Protocols were approved by the Animal Care Committee at the University of Waterloo, with 
all procedures performed in accordance with the Canadian Council on Animal Care. C57Bl/6J 
mice were bred in the Central Animal Facility at the University of Waterloo from founders 
originally purchased from Jackson Laboratories (Bar Harbor, Maine, USA). Fourteen to twenty-
four wk-old female mice were group housed in a controlled environment with constant 
temperature and humidity with a standard 12h light: 12h dark cycle. Animals were provided ad 
libitum with water and a standardized control diet for 9 d (Research Diets #D12450H, New 
Brunswick, New Jersey, USA) prior to experiments. Non-fasted mice were euthanized at 9 am. 
Fasted mice had food withdrawn at 5 pm and were randomized to fast for 4, 8, or 16 h 
overnight, prior to CO2 asphyxiation and tissue collection. 
Assessing Atgl and Hsl mRNA expression  
Total RNA was prepared from whole kidneys using TRI Reagent® (Sigma Aldrich, 
Mississauga, Ontario, Canada). TRI Reagent® was added to a whole kidney and homogenized 
using a Polytron tissue homogenizer to isolate and preserve RNA from cells. Chloroform was 
added and samples were centrifuged to separate RNA from cell constituents. The aqueous 
phase, containing the RNA, was pipetted into a clean tube. Isopropanol was added and samples 
were centrifuged to precipitate the RNA. The RNA pellet was then washed with ethanol, 
resuspended in RNAase free water, and heated for 10 min at 55 °C, to denature RNAases. 
Two g of RNA was reverse transcribed using a high-capacity cDNA reverse transcriptase kit 
(Life Technologies, Burlington, Ontario, Canada) containing a reaction buffer, random primers 
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and dNTP mix and heated in a thermal cycler at 25C for 10min, 37C for 120min, 85C for 5 
min and then kept at 4C. qPCR was performed using SsoFast EvaGreen master mix (Bio-Rad 
Laboratories, Mississauga, Ontario, Canada) containing SsoFast Eva Green super mix, forward 
and reverse primers (Table 1)  and amplified with the conditions: 95C for 2 min, followed by 40 
cycles of 95C for 10 s, 60C for 20 s, followed by melt curve analysis to verify a single amplicon. 
Expression of test genes was normalized to 18s and analyzed by the delta Ct method.  
Table 1: Primer Sets used for PCR reactions 
 
Gene Direction Sequence Product Size 
Atgl forward 5’-aacgccactcacatctacgg-3’ 113 bp 
 reverse 5’-gcctccttggacacctcaata-3’   
     
Hsl forward 5’-ggagtctatgcgcaggagtg-3’ 80 bp 
 reverse 5’-gcttcttcaaggtatctgtgcc-3’   
     
Aox forward 5'-gctgcggagacaggttgtcatcg-3' 105 bp 
 reverse 5'-gctccttgcgcagatcgggattc-3'   
     
Cd36 forward 5'-tcctctgacatttgcaggtccatct-3' 103 bp 
 reverse 5'-aggcaaaggcgttggctggaa-3'   
     
Pparα forward 5'-ccgaacattggtgttcgcagctgt-3' 91 bp 
 reverse 5'-caggggacaaccagaggacccag-3'   
     
ATGL-LoxP  forward 5'-ctcaccgccacagcgctggtcac-3' HM- 315 bp 
 reverse 5'-gtccctctctaccgcttctac-3' HT- 180 bp 
     
KSP-CRE forward 5'-aggttcgttcactcatgga-3' 277 bp 
 reverse 5'-tcgaccagtttagttaccc-3'   
     
Fn1 forward 5'-acatggctttaggcggacaa-3' 75 bp 
 reverse 5'-ttcggcaggtatggtcttgg-3' 
     
  TNF-α forward 5’-caacgccctcctggccaacg-3’ 114 bp 
 reverse 5'-tcggggcagccttgtccctt-3' 
     
  Il-β forward 5'-cctgctggtgtgtgacgttccc-3' 84 bp 
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 reverse 5'-gggtccgacagcacgaggct-3' 
    
   Il-6 forward 5'-gctggagtcacagaaggagtggct-3' 117 bp 
 reverse 5'-ggcataacgcactaggtttgccgag-3' 
     
  18s forward 5’-gatccattggagggcaagtct-3' 79 bp 
 reverse 5’-aactgcagcaactttaatatacgctatt-3’ 
   
Immunodetection of ATGL and HSL 
Whole kidneys were homogenized on ice using a Polytron in lysis buffer (50 mM Tris, pH 
7.4, 0.1 M sucrose, 1 mM EDTA, 5mM sodium fluoride, 10mM sodium orthovanadate, with 
protease inhibitor cocktail (1:100) (Sigma Aldrich, Mississauga, Canada), followed by 
centrifugation at 9,000  g for 15 min at 4°C, and determination of protein concentrations by 
bicinchoninic acid assay (Sigma Aldrich, Mississauga, Canada). Heat denatured lysates in 
Laemmli buffer with 2-mercaptoethanol were electrophoresed through 10% SDS-PAGE gels and 
wet-transferred to nitrocellulose membranes at a constant 350 mA for 90 min. Membranes 
were blocked overnight at 4C with 5% (w/v) blocker in TBST. Membranes incubated for 2 h at 
room temperature with primary antibodies (mouse-Anti-ATGL, Cell Signaling, Danvers, MA, 
USA) (mouse-Anti-HSL, Cell Signaling, Danvers, MA, USA) (mouse-Anti-HSL-S565, Cell Signaling, 
Danvers, MA, USA) (mouse-Anti-HSL-S660, Cell Signaling, Danvers, MA, USA) (mouse-Anti-14-3-
3, Cell Signaling, Danvers, MA, USA) (mouse-Anti-ACC, Cell Signaling, Danvers, MA, USA) 
(mouse-Anti-ACC-S79, Cell Signaling, Danvers, MA, USA) (mouse-Anti-AMPK, Cell Signaling, 
Danvers, MA, USA) (mouse-Anti-HSL, Cell Signaling, Danvers, MA, USA) (mouse-Anti-HSL-S565, 
Cell Signaling, Danvers, MA, USA) (mouse-Anti-HSL-S660, Cell Signaling, Danvers, MA, USA) 
(mouse-Anti-14-3-3, Cell Signaling, Danvers, MA, USA) (mouse-Anti-ACC, Cell Signaling, Danvers, 
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MA, USA) (mouse-Anti-ACC-S79, Cell Signaling, Danvers, MA, USA) (mouse-Anti-Beta-Actin, Cell 
Signaling, Danvers, MA, USA) (1:1000 in TBST with 2% blocker), then washed 3 times in TBST, 
then incubated for 1 h with horseradish peroxidase-conjugated secondary antibodies (Santa 
Cruz Biotechnology, Dallas, TX, USA) (1:5000 in TBST with 2% blocker), then washed 3 times in 
TBST. Immunoblots were visualized by enhanced chemiluminescence on a ChemiGenius 2 Bio-
Imaging System (Syngene Technologies, Palos Heights, IL). Bovine serum albumin (BSA) was 
used as a blocker for phospho-specific antibodies, and skim milk powder was used for all 
others.  
For detection of phosphorylated 14-3-3 binding motif in ATGL, lysates (1000 g) were first 
immunoprecipitated by tumbling overnight at 4 C with rabbit anti-ATGL (1:200), then captured 
by tumbling for 1 h with protein A/G agarose beads. Samples were centrifuged and washed 
with lysis buffer 3 times.  Laemmli buffer with beta-mercaptoethanol was then added to 
immunoprecipitated ATGL samples and heated at 95 C to separate protein from agarose 
beads, and treated as above for SDS-PAGE separation. 
 
In-vitro TAG hydrolase assay 
Reactions were initiated by addition of lysates containing 100 μg of protein in 100 μl of lysis 
buffer to 100 μl of reaction mixture containing 300 μM triolein with [9,10-3H(N)]triolein (0.15 
μCi per reaction) (Perkin Elmer Radiochemicals, Massachusetts, USA), 25 μM egg yolk lecithin, 
100 μM sodium taurocholate, 2% BSA (w/v), 1 mM DTT, and 50 mM potassium phosphate (pH 
7.2) and allowed to react for 1 hr (32,74). Reactions were terminated after 1 h at 37°C by 
addition of 0.25 ml of methanol: chloroform (1:2). Extraction of lipids, by Bligh and Dyer 
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method (75), was performed by vortexing sample after addition of methanol:chloroform, then 
addition and mixing of 0.25 mL of ddH2O, then centrifugation at 1000x g for 5 minutes to 
separate aqueous and organic phases. The organic phase was collected and dried under a N2. 
Samples were reconstituted in 50 μL of chloroform and applied to a silica gel G plate. 
Sseparation of total lipids was performed by thin layer chromatography using hexane: diethyl 
ether: glacial acetic acid (80:20:2). The band corresponding to NEFA was identified by 
comparison with known standards under iodine vapours, scraped, and quantified by liquid 
scintillation counting.  
Beta-Oxidation 
Fresh kidneys were excised, cut sagittally and weighed. Kidney sections were added to a 14 
ml Falcon tube containing 1 ml of Kreb’s buffer (126 mM NaCl, 2.5 mM KCl, 25 mM NaHCO3, 1.2 
mM NaH2PO4, 1.2 mM MgCl2, 2.5 mM CaCl2, pH 7.2) supplemented with 3mM glucose and 1% 
BSA plus 0.1 μCi [14C]palmitic acid. A 500 μl Eppendorf tube was attached to the inside of the 
falcon tube containing a 1x1 cm filter paper soaked in 20% KOH to capture released CO2. Falcon 
tubes were enclosed with parafilm. The reaction was incubated for 1 h at 37 °C with gentle 
shaking. The reactions were stopped at 1 h by adding 0.25ml of H2SO4 (5N) by injection 
through parafilm. Reactions were left covered at 37C for an additional 30 min. The 1x1 cm filter 
papers were scintillation counted for radio-labelled [14C]-CO2. 
 
Immunohistochemistry 
Kidneys were frozen in Cryo O.C.T. compound (Tissue Tek, Fisher Scientific, Mississauga, 
Canada), sliced to 8 μm, adhered to glass microscope slides, then fixed with 4% 
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paraformaldehyde for 10 min, washed with PBS, and permeabilized with 0.5% Triton X-100 for 5 
min. Sections were then washed with PBS, blocked with 5% goat IgG serum in PBS for 1 h, 
incubated at room temperature for an additional hour with rabbit anti-ATGL antibody (1:100) in 
PBS, washed again with PBS, and incubated for 1 h with Alexa Fluor® 488-conjugated anti-
mouse IgG (Cell Signaling, Danvers MA). Sections were stained with DAPI (1 μg/mL) for 15 min, 
and mounted with coverslips using Prolong Antifade (Life Technologies, Burlington, Canada). 
Slides were imaged on an Axio Observer Z1 structured-illumination fluorescent microscope 
equipped with an AxioCam HRm camera and analyzed with AxioVision software (CarlZeiss). 
cAMP Assay 
Kidneys snap frozen in liquid nitrogen were homogenized using a handheld Polytron in 10 
volumes (ml/g tissue) of trichloroacetic acid (5% in water) on ice and then centrifuged at 1,500 
x g, after which the supernatant was transferred to a new glass tube. Samples were then 
extracted using 5-volumes of water-saturated ether per volume of supernatant by vigorous 
vortexing for 10 s, after which the aqueous and organic layers were allowed to separate. The 
upper organic phase was carefully removed and discarded, and the lower aqueous phase was 
extracted twice more. Samples were then heated to 70C for 5 min to evaporate any remaining 
ether, and then cAMP concentrations were determined using a commercially available 
competitive ELISA assay (Cayman Chemical, Ann Arbor, MI, USA). Diluted samples (1:10) were 
added to 96-well plate precoated with anti-rabbit IgG. Samples were then incubated with 
acetylcholinesterase-linked cAMP (tracer) and cAMP antiserum for 18 hours at 4°C. Wells were 
emptied by inverting and tapping plates gently on a hard surface and washed with wash buffer 
five times. Plates were quantified by the addition of Ellman’s Reagent and incubation for 1 h, 
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which reacts with acetylcholinesterase, allowing quantification of its product 5-thio-2-
nitrobenzoic acid, which has strong absorbance at 412 nm. The amount of tracer bound, and 
thus intensity of absorbance, is inversely proportional to the concentration of cAMP in the 
sample because of binding competition between tracer- and sample-cAMP. 
 
Comprehensive Laboratory Animal Monitoring System Measurement 
On the last day of feeding, mice were placed into the Oxymax Comprehensive Laboratory 
Animal Monitoring System (CLAMS, Columbus Instruments) for 24 h. The Oxymax system is an 
open-circuit indirect calorimeter for lab animal research allowing the measurement of oxygen 
consumption (VO2) and respiratory exchange ratio (RER) of mice over 24 h of feeding/fasting 
protocol. Oxygen consumption (VO2) is a measure of the volume of oxygen used to convert 
energy substrate into ATP. Respiratory exchange ratio (RER) is the ratio of carbon dioxide 
production (VCO2) divided by VO2 and is an estimate of the fuel source for energy production 
based on the difference of oxygen molecules required for the oxidation of glucose and fatty 
acid. An RER of 0.7 indicates fat as the primary substrate while an RER of 1.0 indicates 
carbohydrate as the primary energy substrate. Animals were housed individually. For fasted 
animals, food was removed after the mice had acclimatized to the cages for 8 h, and the mice 
were maintained in the cage for an additional 16 h after food withdrawl. 
Statistical Analysis 
Statistically significant differences between two groups (i.e. fasted versus non-fasted) were 
assessed by Student’s t test. Time-dependent effects of fasting on gene expression were 
analyzed by one-way ANOVA with Tukey’s multiple comparison post-hoc test. The results are 
25 
 
expressed as means +/- S.E.M.  Unless otherwise indicated, different groups contain at least 
n=4. Significance is reported as: *P<0.05; **P<0.01; ***P<0.001. Different letters represent 





To determine whether TAG hydrolase activity is present in the kidney, and whether 
changes in that activity are evident with fasting, we investigated the release of radiolabelled 
[3H]oleate from radiolabelled [3H]triolein by kidney homogenates. We found that the hydrolysis 
of TAG by kidney homogenates was significantly induced by 15% with fasting, as compared to 
non-fasted (Figure 2). 
Expression of lipid enzymes in the kidney 
 mRNA expression of Atgl and Hsl in the kidney was analyzed by qPCR analysis and as 
expected, was found to be expressed in whole kidney. We measured relative levels of Atgl and 
Hsl mRNA by qPCR in fasted kidneys after 16 h of food withdrawal, and found a 2.2-, 2.6- fold 
increase, respectively (Figure 3Error! Reference source not found.).  Atgl was increased early in 
fasting, but expression plateaued from 4 to 8 h before increasing further at 16 h, whereas Hsl 
mRNA showed a progressive induction at each time-point measured (P<0.05). 
The expression of other genes in fatty acid metabolism was analyzed for fasting-
mediated regulation. Ppar-alpha, Cd36 and Aox were upregulated 2.4-, 8.2- and 35.7- fold 
following a 16 h fast (P<0.05), with a progressive induction at 4 and 8 h of fasting (Figure 
4Error! Reference source not found.). 
Immunodetection of lipid enzymes 
Total immunodetecable levels of ATGL and HSL were measured and found, in agreement 
with data from mRNA measures, to both be expressed and induced in whole kidney. Following 
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a 16 h fast, there was an approximate 2.4- and 3- fold induction of total ATGL and HSL 
immunodetectable levels, respectively (Figure 5). 
Immunodetection of phosphorylated lipid enzymes 
To investigate whether the activation state of the enzymes involved in lipolysis is 
associated with the fasting-mediated change in lipolysis, we measured levels of phospho-
specific forms of ATGL and HSL.  
We found that fasting mediated an approximate 3-fold increase in levels of 
immunodetectable phospho-ATGL phosphorylated at the 14-3-3 binding domain site in 
immunoprecipitated ATGL. Using phospho- and site-specific antibodies we probed HSl at S565 
and S660. We found a significant 4.5-fold higher content of phosphorylated S565 HSL at this 
position. We also found a 2.5-fold higher content of HSL phosphorylated at serine 660 (S660) 
(Figure 5). 
Immunohistochemical detection of ATGL in kidney cortex and medulla 
To investigate the localization of ATGL in kidney, we performed immunohistochemistry on 
frozen renal tissue sections. ATGL was found be nearly ubiquitously expressed throughout the 
cortex and medulla. ATGL immunopositive cells were evident within glomeruli, cortical tubules 
and medullary rays. Intense fluorescence was marked at the apical/lumenal surface of cortical 
tubule cells (Figure 6). 
Assessment of markers of kinase activity 
 The changes in HSL and ATGL phosphorylation that we observed are predicted to be 
mediated by the kinases PKA and AMPK. PKA is activated by rising cAMP concentrations that 
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can be generated in response to circulating beta-adrenergic receptor agonists that increase 
during fasting (76). We measured cAMP in kidneys from non-fasted and fasted mice, but found 
that concentrations were not significantly different after 16 h of fasting (Figure 7). 
 We next investigated the possible involvement of AMPK in the phosphorylation of ATGL 
and HSL by immunoblotting for total AMPK, phospho-AMPK, and total and phosphospecific 
levels of acetyl-CoA carboxylase (ACC) that is a classical substrate for this kinase (77). Total 
AMPK protein levels were increased by 2.2-fold following a 16 h fast (P<0.05)(Figure 8).  We 
found a small increase in total kidney ACC levels with fasting, but a greater increase in phospho-
ACC that was phosphorylated at the AMPK-specific site Serine 79 (S79) (Figure 9). As a result, 
the ratio of phosphorylated ACC to total ACC increased by almost a third in the fasted state 
relative to the non-fasted state (1.40.1 vs. 1.10.1, P<0.05). 
Respiratory exchange ratio 
 The ratio of carbon dioxide to oxygen consumption was used to calculate the respiratory 
exchange ratio (RER), to provide an estimate of metabolic substrate usage. As expected, after 
16 h of fasting there was a significant reduction in the whole body respiratory exchange ratio 
(RER) from 0.97 in the non-fasted state to 0.74, indicating a shift toward fat as the main 
substrate of energy metabolism (Figure 10). 
Kidney Beta-Oxidation 
 Kidney fatty acid beta-oxidation was measured by reaction of [14C]palmitate with whole 
kidney homogenates, and we found a significant 1.6-fold increase in the amount of membrane 
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captured 14C-labelled CO2 produced from the mitochondrial respiration of radiolabelled 












































Figure 2: Lipolysis activity is increased in kidney following fasting. 
Fasting induces lipolysis in whole kidney homogenates as measured by the generation of free 





Figure 3: Fasting induces renal Atgl and Hsl mRNA. 
Fasting induces mRNA expression of Atgl and Hsl in in a time-dependant manner in female mice 
as determined by qPCR and normalized to 18s. Expression is shown in fed mice (time point 0) 
and after 4, 8, and 16 h of fasting (n=3-6); data are means ± SEM; different letters indicate 





Figure 4: Fasting induces renal mRNA expression of lipid uptake and oxidative genes. 
Fasting induces Ppar-α, Cd36, and Aox mRNA as determined by qPCR and normalized to 18s. 
Expression is shown in fed mice (time point 0) or after 4, 8, and 16 hours (h) of fasting. (n=3-6); 
data are means ± SEM; different letters indicate significant differences between groups as 













Figure 5: TAG lipolysis enzymes in kidney are regulated by fasting.  
Immunoblots of ATGL, phospho-ATGL phosphorylated at the 14-3-3 binding domain, HSL, 
phospho-HSL phosphorylated at S565, phospho-HSL phosphorylated at S660, and control beta-
ACTIN protein levels of non-fasted and fasted female mice. Fasting increases total and site-
specific phosphorylation of ATGL and HSL in whole kidney homogenates (n=3-6); *P<0.05, ** P 











Figure 6: ATGL is immunodetected in kidney sections. 
ATGL was visible by immunodetection in essentially all cell types in kidney sections. Green: Anti-
ATGL, Blue: DAPI (nuclei). Top, left to right: Anti-ATGL alone, DAPI alone, merged image of ATGL 
and DAPI. Middle: Merged image of ATGL and DAPI staining for an axial cross-section of kidney. 
Insets 1 and 2 are magnifications of the merged image. Insets show increased ATGL staining 
intensity on the apical/ lumenal surface of renal tubule. g= glomerular cells; ct= convoluted 














Figure 7: Kidney cAMP concentrations. 
cAMP was isolated from kidneys of non-fasted and fasted mice (16 h) using water-saturated 






































Figure 8: Fasting induces AMPK total protein in kidney. 
Representative immunoblot and quantification of AMPK protein level in non-fasted and fasted 



































Figure 9: Fasting induces phosphorylation in the kidney of the AMPK target ACC at S79. 
Top bands: Representative immunoblots of ACC and phospho-ACC phosphorylated at serine 79 
in non-fasted and fasted mice. Bottom graph: The ratio of phospho-ACC to ACC protein level is 





















Figure 10: Respiratory exchange ratio (RER) in non-fasted and fasted mice. 
The RER ratio of carbon dioxide production to oxygen consumption was measured to assess 
metabolic fuel usage in response to fasting. Fasted mice had lower RERs in response to fasting, 
indicating a shift in fuel usage from predominantly glucose metabolism to fatty acid beta-






























































Figure 11: Whole kidney beta-oxidation. 
Measure of 14CO2 released from 
14C[palmitate] after reaction with kidney homogenates 






To evaluate the suitability of targeting renal ATGL for the development of a lipid droplet 
accumulation model, I first characterized murine renal lipolysis. Here, I report the expression, 
regulation, and post-translational modification of ATGL and HSL, two TAG hydrolase enzymes, 
in murine kidney.  
In agreement with others, I found that mRNA for Atgl and Hsl are expressed in murine 
whole kidney (31,72). I extended these findings by determining that ATGL protein is also 
present in the kidney, and investigated the localization of ATGL within murine kidney 
cryosections, finding ubiquitous expression across all cell types, with ATGL highly expressed in 
glomerular and tubule cells. Of interest, I found that ATGL was particularly concentrated near 
the apical surface of renal tubule cells, so that the action of ATGL in tubules would be 
concentrated around the lumen, where albumin-bound fatty acid reuptake occurs (55,56). To 
determine whether these lipid enzymes were nutritionally regulated in the kidney I performed 
immunoblots of whole kidney homogenates prepared from fasted mice and found that the 
expression of both ATGL and HSL was induced. I also found that transcriptional activation 
progressively increased after food withdrawal. 
The finding of ATGL and HSL expression and nutritional regulation in the kidney suggested 
functional expression to support renal lipolysis. It is known that the kidney relies on fatty acid 
beta-oxidation (78) to meet the high metabolic demand created from regulating osmotic 
balance of the blood (79). I hypothesized that induction of lipolysis would occur to match 
substrate availability with demand since intracellular TAG is an important source of fatty acids 
for oxidative metabolism, particularly in the fasted state. I found total lipase activity was 
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significantly increased following fasting.  Lipolysis is induced in states of elevated metabolic 
demand in order to mobilize fatty acids stored as TAG (16). Stored TAG is an important 
reservoir for fatty acids that can act as substrates for beta-oxidation, phospholipid synthesis, 
gluconeogenesis and signalling molecules. Corroborating my hypothesis of increased lipolysis to 
supply fatty acids as energy substrates, I found that fasting significantly increased renal fatty 
acid beta-oxidation, agreeing with reports that kidney extensively utilizes beta-oxidation for 
energy metabolism in the fasted state (66).  
I also analyzed the expression of other genes involved in fatty acid metabolism for fasting-
mediated regulation. Peroxisome proliferator-activated receptor alpha (Ppar), a master 
regulator of adaptive catabolic changes in lipid metabolism (80), was progressively elevated 
following food withdrawal, as was the Ppar-regulated fatty acid transporter Cd36, and Ppar-
regulated acyl-CoA oxidase (Aox). These genes aid in the uptake and increased metabolism of 
fatty acids (17,63,81), and their expression, like that of Atgl and Hsl, is regulated at least in part 
in response to extracellular signals that change during fasting. However, PPAR-mediated gene 
regulation is also influenced by intracellular signals. In this regard, ATGL has been shown to be 
required for the generation of lipid ligands for PPAR activation (82,83), and ATGL deficiency 
resulted in a decrease in expression of PPAR and gamma target genes in cardiac myocytes 
(84). The induction of ATGL and HSL during fasting may contribute to the increased release of 
lipid ligands in renal cells, and this was likely a factor in the induction of PPAR target genes we 
observed during fasting. 
I investigated kinases that may be involved in the fasting-mediated increase in renal 
lipolysis. We found no significant difference in levels of cAMP, which suggests that cAMP may 
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not be a large contributor to fasting-mediated effects. I did find an increase in total AMPK as 
well as an increase in the ratio of its phosphorylated target protein ACC(S79), implying that the 
fasting-mediated increase in renal lipolysis may be regulated by an induction of AMPK. AMPK 
acts as a cellular energy sensor and may be signalling to increase activity of ATGL through 
phosphorylation at the S406 site, to increase the supply of fatty acids for beta oxidation. 
To support the notion that lipolysis is induced to match substrate supply with metabolic 
demand, we measured whole body oxygen consumption and carbon dioxide production and 
found, as expected, a reduction in RER, representing a shift towards the use of fatty acids as the 
main substrate for energy metabolism. The shift in whole body metabolism towards lipid 
oxidation serves to decrease the demand on glucose metabolism in most tissues, including 
kidney, in order to conserve glucose for brain energy metabolism.  
The classical pathway of ATGL/HSL-mediated lipolysis is thus present and regulated by 
changing nutritional state within the kidney, indicating a role for lipolysis in kidney function. 
Given the importance of fatty acids to renal energy metabolism as well as the toxicity of excess 
stored lipid, these findings suggest that further investigation of the role of ATGL and HSL in 




CHAPTER 4 – Kidney renal tubule-specific ATGL ablation alters glycemic control in male mice. 
Rationale 
Renal accumulation of fatty acids during fasting occurs in excess of levels used for oxidation, 
leading to increased intracellular TAG (TAG) stores that must subsequently be hydrolyzed for 
use (57,67). Impaired hydrolysis, therefore, would be predicted to lead to TAG accumulation. I 
found ATGL mRNA and protein to be expressed in whole kidney homogenates, and I observed 
ATGL to be present in essentially all regions of the kidney cortex and medulla, including renal 
tubules. Therefore, I identified ATGL as a potentially important mediator of renal TAG 
hydrolysis. To determine whether ATGL is critical for renal tubule lipolysis, and to further 
determine whether disruption of renal tubule lipolysis causes evidence of the early pathology 
of CKD and the CKD-associated co-morbidities diabetes and CVD, I created a model of renal lipid 
accumulation by renal tubule-specific ablation of ATGL. Here, I describe the work completed to 
create kidney renal tubule-specific ATGL knockout (KSAKO) mice, and my initial characterization 
of the consequences of altered renal lipolysis. 
Objectives 
To create and complete initial characterization of KSAKO mice as a model of lipid droplet 
accumulation. 
Characterization will include investigating: 
i. Body and tissue weights 
ii. Renal expression of enzymes in lipolysis  
iii. Renal expression of markers of fibrosis 
iv. Renal expression of markers of inflammation 
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v. Kidney total TAG content 
vi. Glucose tolerance and insulin sensitivity at ages 9 and 16 weeks 
vii. Blood TAG concentrations 
Hypotheses 
Renal tubule-specific ATGL ablation will result in: 
 
1. An increase in kidney mass, and a decrease in white adipose tissue mass, resulting in 
a lower body mass compared to wildtype (WT) mice. 
2. A 30-50% decrease in total kidney ATGL protein level, but a compensatory induction 
of HSL by 20 weeks of age. 
3. An increase in the mRNA expression of markers of fibrosis in the kidney by 20 weeks 
of age. 
4. An increase in the mRNA expression of markers of inflammation in the kidney by 20 
weeks of age. 
5. An increase in kidney TAG concentration by 20 weeks of age. 
6. Improved glucose tolerance and insulin sensitivity at 9 weeks of age, but impaired 
glucose tolerance and insulin sensitivity at 16 weeks of age. 







All animal use protocols were approved by the Animal Care Committee at the University of 
Waterloo, with all procedures performed in accordance with the Canadian Council on Animal 
Care. Mice were bred in the Central Animal Facility at the University of Waterloo and were 
group housed in a controlled environment with constant temperature and humidity with a 
standard 12h light: 12h dark cycle. Male animals between 9-23 weeks of age were used for this 
study. Animals were provided ad libitum with water and a standardized chow diet prior to 
experiments. Fasted mice had food withdrawn at 5 pm and were fasted for 16 h overnight, 
prior to CO2 asphyxiation and tissue collection. 
 
ATGL Knockout Design 
The generation of KSAKO utilized the Cre-LoxP-recombination system to excise the catalytic 
region of ATGL. ATGL flox/flox mice that were generously donated by Dr. Hei Sook Sul have loxP 
sites flanking the entire first exon that contains the serine/aspartate catalytic dyad (Figure 12). 
These mice have been backcrossed for greater than 6 generations onto a C57Bl/6J background 
strain. In the absence of cellular cre-recombinase expression, the ATGL floxed gene is functional 
in all tissues of the body. We bred ATGL flox/flox mice at the University of Waterloo Central 
Animal Facility with commercially available transgenic mice that express cre-recombinase under 
control of the kidney-specific (Ksp) cadherin/cadherin 16 promoter (B6.Cg-Tg(Cdh16-cre)91Igr/J 
from Jackson Laboratories). These mice are also fully backcrossed (>9 generations) onto a 
C57Bl/6J background. Transgenic Cdh16-cre mice primarily express cre-recombinase in renal 
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tubule cells and glomeruli, and have been used previously to produce renal tubule-specific 
knockout mouse models (85,86). The expression of CRE recombinase in the presence of repeat 
LoxP sites results in the joining of LoxP sites and the deletion of the LoxP flanked region (Figure 
12). 
 
Figure 12: CRE Recombination of LoxP sites over exon 1 of Atgl. 
To produce our KSAKO mice we first bred mice heterozygous for Cre recombinase with mice 
homozygous for the Atgl floxed allele. The progeny mice were genotyped for the presence of 
CRE recombinase and for heterozygosity of the Atgl floxed allele, and were backcrossed with 
mice heterozygous for the Atgl floxed allele, but lacking Cre, in order to generate mice 
homozygous for the Atgl floxed allele, with and without Cre. These mice were selected to 
become the parent generation of our study animals. Two principal breeding strategies were 
employed for our study generations. Breeding strategy 1: Mice homozygous for the Atgl floxed 
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allele and transgenic for Cre recombinase were mated with mice heterozygous for the Atgl 
floxed allele but lacking the Cre recombinase transgene to produce 25% KSAKO, 25% Htz, and 
50% WT mice (Figure 13). KSAKO mice are progeny that are homozygous for the Atgl floxed 
allele, and transgenic for Cre recombinase. Mice heterozygous deficient in ATGL (Htz) mice are 
heterozygous for the ATGL floxed allele, and transgenic for Cre recombinase. Wildtype (WT) 
mice are not transgenic for Cre recombinase. WT mice may be either homozygous or 
heterozygous for the Atgl floxed allele, but in the absence of CRE Recombinase, the LoxP sites 
do not recombine and do not affect the structure or function of the gene, making these mice 
indistinguishable from unaltered C57Bl/6J mice. Breeding strategy 2: Mice homozygous for the 
Atgl floxed allele and transgenic for Cre recombinase were mated with mice homozygous for 
the Atgl floxed allele but lacking the transgene for Cre recombinase to produce 50% KSAKO and 
50% WT mice (Figure 14). 
 
Figure 13: Breeding Strategy 1.  
Left side: Mice homozygous for floxed Atgl and transgenic for Cre were mated with mice 
heterozygous for floxed Atgl and lacking the Cre transgene. The predicted progeny are 
illustrated on the Right side. Solid arrow heads illustrate LoxP sites flanking exon 1 of Atgl. 






Figure 14: Breeding Strategy 2.  
Left side:  Mice homozygous for floxed Atgl and transgenic for Cre recombinase were mated 
with mice homozygous for floxed Atgl and lacking the Cre recombinase transgene. The 
predicted progeny are illustrated on the Right side. Solid arrow heads illustrate LoxP sites 




Ear notches were taken from 4 week old mice and frozen in a -80C freezer until processing. 
DNA was extracted from the ear notches using a NaOH extraction procedure (87). NaOH was 
added to the ear notches and they were heated at 95°C for 1 h, then Tris–EDTA was added to 
neutralize the samples. Samples were stored at -20°C or used immediately. DNA samples were 
added to a mixture of Taq Polymerase (Sigma-Aldridge), containing MgCl2, dNTPs, H2O, and the 
appropriate forward and reverse primers (Table 1 ). Samples were placed in a thermal cycler 
(BIO-RAD) and denatured for 5 min at 95°C, then cycled for 30 cycles of denaturing for 30 s at 
95°C, annealing for 30 s at 60°C, and extension for 45 s at 72°C. Following amplification, 
samples were loaded and separated in a 2% agarose gel containing 0.01% ethidium bromide 
(Sigma), and then imaged using the ChemiGenius 2 Bio-Imaging System (Syngene).  
It should be noted that genotyping for knockout animals was challenging because the gene 
is excised only in certain cell types of the kidneys of mice expressing CRE Recombinase.  Thus, 
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ear notches of mice contain the full Atgl gene that is flanked by LoxP sites, but that has not had 
exon 1 removed. The LoxP sequence is only 34 bp in length, which constitutes a relatively small 
genetic modification (Figure 15). Therefore, I devised a PCR-based genotyping protocol based 
on size differences produced by the presence of the LoxP site and associated vector DNA in the 
3’ region of exon 1. PCR for the mutant allele results in the amplification of a 315 bp amplicon 
containing a region of exon 1 along with the LoxP site in the centre. PCR for the wildtype allele 
goes over a region that does not contain the LoxP site resulting in a smaller amplicon of length 
180 bp. Mice homozygous for the Atgl floxed allele contained a band that was 315 bp in size, 
while heterozygous mice contained a band at both 315 bp and 180 bp. Mice lacking the LoxP 
sites were not expected or observed in our genotyping. 
We genotyped mice for the Cre recombinase gene using PCR. PCR for Cre recombinase 
resulted in the generation of a 270 bp amplicon in mice carrying the transgene. When 
combined with genotyping results for the floxed allele, this allowed us to identify KSAKO, Htz 




Figure 15: Primer Design for genotyping.  
PCR across a region of DNA containing the LoxP site and associated vector DNA in floxed mice 
identified a 315 bp band. A 180 bp band is generated when the LoxP site is absent. 
 
Adipose Tissue Depot Collection 
Mice were euthanized and blood was taken by cardiac puncture. Mice were then laid in a 
dorsal recumbent position on the dissection table. A sagittal incision was made from the 
sternum to the lower pelvis region. The adipose tissue surrounding the intestinal walls, termed 
visceral adipose tissue, was removed by carefully peeling the adipose away from the intestines 
using fine tweezers. After removing the visceral adipose tissue the kidneys were exposed. The 
kidneys were removed with adipose tissue attached, and then the adipose surrounding the 
kidney, termed peri-renal adipose tissue, was excised with fine tweezers. The adipose tissue 
dorsal to the kidneys and lying next to the spine, termed retroperitoneal adipose tissue, was 
then removed. The gonadal adipose, posterior to the kidneys and surrounding the pelvic region 
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was excised and carefully dissected from reproductive organs. For collection of subcutaneous 
adipose, while holding the rib cage, the outer layer of skin was peeled away to expose the 
subcutaneous adipose tissue.  The two subcutaneous adipose tissue depots collected lay next 
to the ribcage and posterior to this in the hind region. The mouse was then laid in ventral 
recumbency on the dissection table and a sagittal incision was made along the spine and the 
outer layer of skin was held open. The adipose tissue depot between the shoulder blades, 
termed brown adipose tissue, was excised with careful attention to remove the adipose depot 










Whole kidneys were homogenized on ice using a Polytron tissue homogenizer in lysis buffer 
(150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris, 1% Triton X100, pH 8.0) with 
protease inhibitor cocktail (1:100) (Sigma Aldrich, Mississauga, Canada), followed by 
centrifugation at 9,000  g for 15 min at 4°C. Sample protein concentrations were determined 
by bicinchoninic acid assay (Sigma Aldrich, Mississauga, Canada). Laemmli buffer with 2-
mercaptoethanol was added to samples followed by heat denaturing at 95 °C for 5 min. 
Samples were electrophoresed through 10% SDS-PAGE gels and wet-transferred to 
nitrocellulose membranes at a constant 350 mA for 90 min. Membranes were blocked 
overnight at 4C with 5% (w/v) skim milk blocker in TBST. Membranes were then incubated, 
shaking for 2 h at room temperature with primary antibodies (mouse-Anti-ATGL, Cell Signaling, 
Danvers, MA, USA) (1:1000 in TBST with 2% blocker). Membranes were washed 3 times in TBST, 
then incubated for 1 h with horseradish peroxidase-conjugated secondary antibodies (Santa 
Cruz Biotechnology, Dallas, TX, USA) (1:5000 in TBST with 2% skim milk blocker). Membranes 
were washed 3 times with TBST. Immunoblots were visualized by enhanced chemiluminescence 
on a ChemiGenius 2 Bio-Imaging System (Syngene).  
RT-qPCR 
Total RNA was extracted from whole kidneys using TRI Reagent® (Sigma Aldrich, 
Mississauga, Ontario, Canada). Whole kidney was homogenized using a Polytron tissue 
homogenizer to isolate RNA from cells. Chloroform was added to samples to separate RNA from 
cell constituents. The aqueous phase, containing the RNA, was collected. Isopropanol was 
added to precipitate the RNA. The RNA pellet was washed with ethanol, resuspended in 
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RNAase free water, and heated for 10 min at 55°C, to denature RNAases. Two micrograms of 
RNA was reverse transcribed using a high-capacity cDNA reverse transcriptase kit (Life 
Technologies, Burlington, Ontario, Canada) containing a reaction buffer, random primers and 
dNTP mix and heated in a thermal cycler at 25C for 10 min, 37C for 120 min, 85C for 5 min 
and then kept at 4C. qPCR was performed using SsoFast EvaGreen master mix (Bio-Rad 
Laboratories, Mississauga, Ontario, Canada) containing SsoFast Eva Green super mix, forward 
and revers primers (TABLE)  and amplified with the conditions: 95C for 2 min, followed by 40 
cycles of 95C for 10 s, 60C for 20 s, followed by melt curve analysis to verify a single amplicon. 
Expression of test genes were normalized to 18s and analyzed by the delta Ct method.  
Whole Kidney TAG quantification 
Total lipid extraction was performed on whole kidneys according to the method of Folch 
(88). Whole kidneys were homogenized in 2:1 chloroform: methanol.  After homogenization, 
sodium phosphate was added and the aqueous and organic layers were allowed to separate.  A 
second extraction was performed to remove contaminants. The organic layer was aliquotted 
and dried down. The lipid was then resuspended in chloroform and spotted onto a silica gel G 
plate along with standards and resolved by thin layer chromatography in a hexane: diethyl 
ether:acetic acid (80:20:2) solvent front. Bands corresponding to TAG were identified with the 
standards and scraped for quantification by gas-phase chromatography. 
Glucose Tolerance Testing 
To perform glucose tolerance testing, mice were fasted overnight with food removal at 6pm 
on the evening prior to testing. Blood glucose values were measured using an ACCU-CHEK® 
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Aviva Nano glucose monitor (Roche Technologies, Basel, Switzerland) with blood drop samples 
obtained by tail prick (~3 µl). Fasting glucose measures were recorded at 12 pm. Following 
fasting glucose measurement i.p. injections of sterile 20% D-glucose solutions, prepared fresh, 
were given using 25 gauge (2/3 inch) injection needles. Dosages were based on weight of the 
animal at 2 mg glucose per gram body weight. Injections were spaced 5 min apart to allow for 
measurement time. Blood glucose readings were taken at 15, 30, 45, 60, 90, and 120 min after 
glucose i.p. injection. 
Insulin Tolerance Testing 
To perform insulin tolerance testing, mice were fasted for 5 hr on the morning of testing, 
with food removal at 8 am. Blood glucose values were measured using an ACCU-CHEK® Aviva 
Nano glucose monitor (Roche Technologies, Basel, Switzerland) with blood drop samples 
obtained by tail prick (~3µl). Baseline fasting glucose measures were recorded at 1 pm. 
Following the fasting glucose measure mice were given i.p. injections of a sterile 50 mU stock 
insulin solution with 25 gauge (2/3 inch) injection needle. Insulin solutions were prepared fresh 
in 1X sterile PBS.  Dosages were based on weight of the animal at 0.5 mU insulin per gram of 
body weight. Injections were initiated 5 min apart to allow for measurement time. Blood 
glucose readings were taken at 15, 30, 45, 60, 90, 120 min after insulin i.p. injection. 
Plasma Lipid Determination 
Blood from animals was collected via cardiac puncture and spun at 1,500 rpm to separate 
plasma. Plasma was frozen at -80 degrees for further processing. A triglyceride quantification 
assay kit was used to assess plasma TAG (Cayman Chemical, Ann Arbor, MI, USA). 10 µl of 
plasma sample was added 150 µl of enzyme buffer solution. The enzyme buffer solution 
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contains lipase which hydrolyzes TAG to glycerol and free fatty acids. The glycerol is measured 
by a coupled enzymatic reaction that forms hydrogen peroxide. A peroxidase then catalyzes the 
redox-coupled reaction of hydrogen peroxide with a dye, producing a bright purple color. The 
assay was incubated at room temperature for 15 min protected from light. The reactions were 
quantified by measurement in a microplate reader at 550 nm. Sample readings were converted 
to TAG concentrations using a standard curve generated using standards supplied with the 
assay kit. 
Statistical Analysis 
Mice were divided into two groups based on expression of ATGL (WT vs KSAKO). Statistically 
significant differences between two groups were assessed by Student’s t test. The results are 
expressed as means +/- S.E.M.  Unless indicated, different groups contain at least three animals 
per group, although up to 22 animals per group were used for some experiments. Significance is 






ATGL reduction in KSAKO mouse kidney 
The relative expression of ATGL was determined in KSAKO mouse kidneys by qRT-PCR and 
western blot analysis. Atgl mRNA was found to be 25% lower in KSAKO mouse whole kidney 
homogenates than in WT kidney homogenates (P<0.05) (Figure 19). The total protein level of 
ATGL in KSAKO mouse kidneys was found to be decreased by 33% (P<0.01) (Figure 20, 21). 
ATGL expression in other tissues 
To determine whether our model of Atgl knockout was indeed renal tubule-specific, we 
assessed the expression of ATGL in additional tissues. We found no decrease in 
immunodetectable levels of ATGL protein in heart (Figure 22). However, there was a significant 
increase in peri-renal ATGL protein, by 248% (P<0.01) (Figure 23, Figure 24). 
HSL expression in KSAKO mouse kidney 
Induction of other TAG lipases could compensate, at least in part, for loss of Atgl. The 
relative expression of Hsl was determined in KSAKO mouse kidneys by qRT-PCR. The relative 
expression of Hsl mRNA in KSAKO mice kidneys was found to be induced by 74% (P<0.05) 
(Figure 25). 
Body Weights 
Animal body weights were measured weekly for 20 wks (Figure 26), and no significant 
difference in body weight was detected at any single time point (Figure 27). However, analysis 
of the incremental change in body weights by analysis of areas under the curve demonstrated 




Tissues were excised and weighed from 20 wk-old mice that had been fasted for 16 h 
overnight. KSAKO kidney and liver weights were both increased by ~12% compared to WT mice 
(P<0.05).  The heart, spleen, and lungs of KSAKO mice were not significantly different in weight 
between WT and KSAKO mice (P>0.05) (Figure 29). 
Adipose tissue depots were excised and weighed. We found the following significant 
(P<0.05) decreases in KSAKO adipose tissue masses compared to WT tissues:  BAT (17%), 
subcutaneous (45%), peri-renal (86%), and retro-peritoneal (81%). The gonadal and visceral 
adipose depots did not significantly differ in weight between WT and KSAKO mice (Figure 30).  
Inflammatory marker mRNA expression in KSAKO mouse kidney 
Impaired TAG hydrolysis is expected to cause TAG accumulation with lipotoxic 
consequences including cell and tissue damage that may stimulate an immune response. The 
relative mRNA expression of inflammatory markers, including Il-6, Il-1b, and TNF-alpha was 
determined by qRT-PCR. The relative expression of Il-6 was induced by 312% in KSAKO kidney 
compared to WT mice (P<0.01). The relative expression of Il-1b and TNF-alpha were unchanged 
in KSAKO kidney compared to WT mice. Fibrosis is also commonly induced in kidney in response 
to cellular or tissue injury, and typically accompanies or follows immunocyte infiltration. The 
relative expression of fibronectin in KSAKO kidney was induced by 38% compared to WT mice 





TAG levels in kidney tissue 
TAG levels in KSAKO kidney tissue not found to be significantly different from WT mice at 20 
wks as measured by lipid extraction and gas chromatography (Figure 32). TAG levels in renal 
tubules, specifically, were not analyzed. 
Serum TAG concentration 
Serum TAG concentration was measured in WT and KSAKO mice at 20 wks using a 
colorimetric protocol. Serum TAG concentration were increased by 25% however this was not 
found to be significantly different in KSAKO mice compared to WT mice (Figure 33). 
Glucose Tolerance and Insulin Sensitivity 
Glucose tolerance testing was performed on mice after a 16 h overnight fast. At 9 weeks of 
age, after intraperitoneal glucose injection, KSAKO mice had a significantly lower plasma 
glucose response compared to WT mice as assessed by area under the curve (P<0.05). KSAKO 
mice had significantly lower plasma glucose concentrations at 30 and 45 minutes after glucose 
injection (P<0.05) (Figure 34). At 16 weeks of age, after intraperitoneal glucose injection, KSAKO 
mice had a significantly elevated plasma glucose response compared to WT mice as assessed by 
area under the curve (P<0.05). KSAKO mice had significantly elevated plasma glucose 
concentrations at 15, 30 and 45 minutes after glucose injection (P<0.05) (Figure 36). 
Insulin tolerance testing was performed on mice after a 5 h fast. At 9 weeks of age, after i.p. 
insulin injection, KSAKO mice had a significantly lower plasma glucose level compared to WT 
mice as assessed by area under the curve (P<0.05). Specifically, KSAKO mice had significantly 
lower plasma glucose concentrations at 30, 45, 90 and 120 minutes after insulin injection 
59 
 
(P<0.05) (Figure 35). At 16 weeks of age, after i.p. insulin injection, KSAKO mice had a 
significantly higher plasma glucose level compared to WT mice as assessed by area under the 
curve (P<0.05). KSAKO mice had significantly elevated plasma glucose concentrations at 30 and 











Figure 17: ATGL genotyping for presence of the floxed allele. 
Genotyping for the Atgl floxed allele to distinguish heterozygotes from homozygotes was 
performed by PCR and gel electrophoresis. Mice homozygous for the Atgl floxed allele 
amplified a single band at 315 bp. Mice heterozygous for the Atgl floxed allele gave two bands 






Figure 18: Cre genotyping. 
Genotyping for the Cre recombinase gene to further distinguish KSAKO or Htz mice from WT 
mice was determined by PCR and gel electrophoresis. Mice transgenic for Cre show a bright 
band at 270 bp whereas mice that lack Cre show no band. WT= no Cre transgene, += Cre 









































Figure 19: ATGL mRNA expression in kidney. 





Figure 20: Kidney ATGL protein level in WT and KSAKO mice. 
Immunoblot of ATGL (~54 kDa) protein in 20 wk old WT and KSAKO mouse kidneys. Red bars 




























Figure 21: Quantification of ATGL protein in kidney. 
Immunoblot quantification of ATGL protein level in kidneys of male mice (20 wks). ATGL protein 









Figure 22: Heart ATGL protein level in KSAKO mice. 
Immunoblot of ATGL (~54 kDa) protein in heart tissue of WT, Htz, and KSAKO mice at 20 wks of 








Figure 23: ATGL protein level in peri-renal white adipose tissue. 
Immunoblot of ATGL (~54 kDa) protein in peri-renal adipose tissue of WT, Htz, and KSAKO mice 
at 20 wks of age. β-Actin (42 kDa) is shown as a loading control to indicate that the greater 












































Figure 24: Quantification of peri-renal adipose tissue ATGL protein level. 
Quantification of peri-renal adipose tissue ATGL protein level in WT and KSAKO male mice (20 
wks). ATGL protein level is increased in peri-renal adipose tissue of KSAKO mice compared to 









































Figure 25: Expression of Hsl mRNA in kidney. 
Gene expression of Hsl mRNA in kidney tissue of KSAKO mice compared to WT mice (20 wks) as 


























Figure 26: Body weight of KSAKO mice. 

























Figure 27: Body weight of KSAKO mice at 20wks. 
Body weights of WT, Htz, and KSAKO male mice at 20 wks of age. There were no significant 
































Figure 28: Area under curve analysis of body weights for KSAKO mice. 
Area under the curve analysis of KSAKO male mice body weights over the first 4-20 weeks of 
life. KSAKO mice had a significantly larger area under the curve compared to WT mice (P<0.05). 
Htz mice had an intermediate phenotype that did not differ significantly from either WT or 













































Figure 29: Tissue weights in KSAKO mice. 
Tissue weights of male WT and KSAKO mice at 20 wks of age. The kidney and liver weights were 
significantly greater in KSAKO than WT mice. There were no significant differences between 




























































Figure 30: Adipose tissue depot masses in KSAKO mice. 
Adipose tissue depots weights of male WT and KSAKO mice, age 20 wks. KSAKO mice had 
significantly lower brown adipose tissue (BAT), perirenal and retroperitoneal (retro), and 
subcutaneous (subcu) tissue weights compared to WT mice. There were no significant 
differences in gonadal and visceral adipose tissue weights between WT and KSAKO mice. BAT = 





































































































































Figure 31: Gene expression of markers of inflammation and fibrosis. 
mRNA expression was assessed by qPCR in 20 wk old WT and KSAKO male mice and normalized 
































Figure 32: Kidney TAG content. 
Kidney TAG was determined by measuring the total free fatty acid content in this lipid species 
by gas chromatography. No significant differences were detected in the TAG content of kidneys 


























Figure 33: Serum TAG concentrations in 20 wk-old WT, Htz and KSAKO mice. 
There was an ~25% increase in serum TAG concentration in KSAKO mice compared to wildtype 





























Figure 34: Glucose tolerance testing in 9 wk old mice. 

























































Figure 35: Insulin tolerance in 9 wk old mice. 

































Figure 36: Glucose tolerance in 16 wk old mice. 
Blood glucose response to i.p. injection of glucose in WT and KSAKO male mice at 16 wks of 

























































Figure 37: Insulin tolerance in 16 wk old mice. 







The reported link between early renal dysfunction and lipid accumulation, as well as the 
association between obesity, ectopic renal lipid accumulation and CKD, has led us to 
hypothesize a role for lipid accumulation and lipotoxicity as an initiating defect in renal disease. 
To study the effects of lipid droplet accumulation and renal lipotoxicity in the absence of 
confounding factors we require a renal tubule-specific model, and therefore a renal tubule-
specific target to elicit lipid accumulation. Previous studies have identified the ablation of 
intracellular lipases such as ATGL and HSL as models for lipid accumulation (25,89). The global 
disruption of ATGL results in TAG accumulation in most tissues, and animals prematurely die of 
cardiac failure due to lipid accumulation in the heart, where the most severe steatosis occurs 
(25). The second largest effect of TAG accumulation in this model occurred in the kidney. 
However, it was unclear whether this effect was due to a specific renal ATGL deficit or to the 
global dysfunction in lipid metabolism that was evident in that model. After characterizing 
lipolysis in the kidney we discovered evidence suggesting that renal Atgl would likely be a 
suitable genetic target for ablation in order to create a model of lipid accumulation in the 
kidney.  
We utilized the Cre-Lox-P system to excise the first exon of Atgl in the kidney using Cre 
recombinase under control of the renal tubule-specific Cdh16 promoter (85,86). This created a 
model of murine ATGL knockout primarily in proximal tubules and glomerular cells that we 
termed kidney renal tubule-specific ATGL Knockout (KSAKO). We confirmed that this led to a 
reduction in Atgl in kidney by analysis of mRNA expression and protein levels. A 25% reduction 
of Atgl mRNA and a 33% reduction in ATGL protein level in whole kidneys were evident. The 
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partial reduction was expected, rather than complete ablation, because Cre-recombinase 
expression was targeted primarily to proximal tubule cells rather than all renal cell types. We 
confirmed that our model is renal tubule-specific by immunoblotting for ATGL in other tissues 
as well (i.e. heart and adipose) and found no decrease in expression across WT, Htz, and KSAKO 
mice. 
Targeted ATGL ablation resulted in a non-significant change in body weight in the KSAKO 
mice by 20 weeks of age. However, area under the curve analysis suggests that KSAKO mice 
gained weight faster, perhaps due to lipid accumulation. To further investigate the change in 
body weight we assessed tissue weight gain under fasted conditions. We observed an increase 
in KSAKO kidney and liver weights with no change in heart or spleen. The increase in kidney 
weights suggested lipid accumulation, which we were expecting to find. However, when the 
kidneys were subjected to lipid extraction and analysis it was found that TAG levels were not 
different between WT and KSAKO mice. The expected increase in TAG may not have been 
evident in the entire kidney because ATGL loss from the kidney was relatively mild and specific 
only to renal proximal tubule and glomerular cells, resulting in a diluting effect by the many 
other cell types with normal Atgl expression. Lipid accumulation in the kidney has previously 
been reported to increase in the fasted stated (67), which may also have lowered the sensitivity 
of detecting differences in lipid levels between WT and KSAKO mice. Accordingly, this analysis 
should be reproduced with kidneys from fed mice, where the difference between TAG in KSAKO 
and WT mice may be greater. More sensitive measures should also be employed, such as 
histochemistry, in order to identify specific cells types with elevated TAG storage. Additionally, 
other time points should be considered for analysis of renal TAG. This measure was taken at a 
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single time point (20 weeks) at which time we also found a compensatory increase in Hsl 
expression that may have reduced the severity of lipid accumulation, although this effect was 
not sufficient to rescue the complex phenotype that these mice developed.  
Any change in body weight suggests a possible alteration to lipid storage by adipose tissue. 
To determine differences in adipose tissue mass we excised specific depots and found 
decreases in various subcutaneous and visceral white adipose tissue depots, and BAT. This 
finding does not explain the relative increase in body mass that was evident in KSAKO mice, but 
it is in agreement with findings of reduced adiposity in CKD, which in some reports occurs in 
association with increased lipolysis (90). To investigate a potential role for increased lipolysis in 
mediating effects in the current study, we assessed the level of ATGL and found that it was 
significantly induced in KSAKO peri-renal WAT. The induction of ATGL in WAT therefore likely 
contributed to an elevation of lipolysis, and a reduction in the weight of WAT depots. The 
reduction of mass of peri-renal and other visceral fat depots in our KSAKO model parallels that 
of visceral tissue loss in patients with CKD (91) and animal models of CKD (92). The loss of 
visceral adipose tissue mass in models of CKD has also been associated with a downregulation 
of WAT lipoprotein lipase (LPL) (93), and an increase in circulating inhibitors of this enzyme (94) 
(95), (93). Whether this effect contributes to the decrease in mass of WAT depots from our 
KSAKO mice remains to be tested.   
KSAKO mice exhibited reduced WAT mass with preliminary evidence of elevated and 
dysregulated lipolysis. Two possible mechanisms include the leakage of uremic toxins from the 
urinary filtrate back into the blood (93,94,96,97), and the release of microRNAs (miRNAs) 
resulting from kidney dysfunction (98). Uremia is a condition where excess urea, creatinine, and 
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other nitrogenous compounds that would normally be found in the urine accumulate in the 
blood, and it is a common pathology of CKD that is also associated with the development of 
insulin resistance. Uremic proteins may be responsible for direct interruption of AKT signalling 
in cells, promoting insulin resistance (99). However, uremic proteins have also been shown to 
induce lipolysis in cultured adipocytes (96), which may promote WAT lipid depletion. If this lipid 
becomes redistributed to skeletal muscle and liver, it may also contribute to development of 
the insulin resistance that is evident in our model. Further studies will be required to determine 
if this is the case. 
Micro RNAs (miRNAs) are recently identified players in metabolic signalling.  MiRNAs are 
small non-coding RNA post-transcriptional regulators that can be released from tissues like the 
kidney into the blood, where they are then able to vastly act at distal organ sites to vastly affect 
gene regulation, since more than half of human protein-coding genes contain miRNA target 
sites in their 3’ untranslated region. In this regard, miRNAs are potentially able to modulate the 
pathology of many conditions in health and disease (100). Changes to adipose tissue mass that 
are evident in KSAKO mice may be the result of changing concentrations of circulating miRNAs 
originating from the kidney. In our model, we saw a similar change in adipose tissue mass, 
accompanied by development of insulin resistance, to that observed in HIV, cancer cachexia 
and aging (92,101-103).  MiRNAs that have been implicated in mediating metabolic events in 
these conditions include miRNA133, 143, 145, 21 (104-106).  Both 143 and 145 play a role in 
modulating adipocyte activity. MiRNA143 has been shown to induce adipocyte differentiation 
(107), and a decreased circulating concentration may have a negative impact on the ability to 
store lipid. MiR145 decreases lipolysis in adipocytes (108). Lower concentrations in the plasma 
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may therefore contribute to reduced inhibition, and thus an inappropriate increase in lipolysis 
as is seen in these conditions. Other candidate miRNAs may play a role in metabolic and 
pathological changes originating in kidneys of KSAKO mice. For example, MiR21 has been 
shown to decrease PPAR ligand-activation by inhibiting lipid metabolism, and the silencing of 
MiR21 has been found to limit renal fibrosis (105). MiR486 is decreased in CKD and it is able to 
inactivate the transcription factor FOXO (109), which has been shown to activate lipolysis in 
adipocytes (110). The modulation of lipid metabolism genes by miRNAs altered in CKD suggests 
a renal-adipose axis, and whether MiR486 or other miRNAs originating from the kidney play a 
role in dysregulated WAT lipolysis in KSAKO mice should be investigated. 
Dysregulated WAT metabolism may cause other metabolic problems, including elevated 
circulating TAG that is a common pathological change in kidney disease. The same factors that 
contribute to decreased adipose tissue mass are mechanistically implicated in increasing 
circulating TAG. Impaired WAT LPL-mediated clearance of circulating TAG (93) can result in a 
prolonged post-prandial rise in fat-rich lipoproteins, while elevated lipolysis increases 
circulating NEFA that drive hepatic VLDL synthesis. Because a loss of WAT was evident in our 
model, we assessed plasma TAG, and found evidence of increased concentrations in both 
KSAKO mice and Htz that we believe will reach significance with a larger samples size. Although 
we did not yet measure serum NEFA, our finding of increased lipase expression and reduced 
WAT depot size suggests that this blood lipid is also altered in KSAKO mice, and should be 
directly analyzed. Elevated serum NEFA, as well as elevated circulating TAG, are implicated in 
the generation of lipotoxic environments and the development of insulin resistance (21,22). 
Importantly, patients with ESRD, but no prior history of diabetes, are at increased risk of 
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developing the disease (10,11), strongly suggesting a link with events in the kidney, although 
these are currently poorly defined.  
We assessed glycemic control in our KSAKO model by measuring glucose tolerance and 
insulin sensitivity at 9 weeks and 16 weeks of age. At 9 weeks, KSAKO mice cleared injected 
glucose faster than WT mice. This may indicate a renal-tubule-specific, and insulin-independent 
effect demonstrating improved utilization of glucose by the kidneys, where ATGL loss would 
limit the provision of competing fatty acid substrates for beta-oxidation. However, KSAKO mice 
also exhibited better insulin-dependent glucose disposal, demonstrating a larger and more 
rapid blood glucose decrease in response to i.p. insulin injection than wildtype mice. It is 
therefore likely that tissues other than the kidney are also involved in mediating this effect, 
since the only cells in the kidney that are responsive to the action of insulin for the regulation of 
glucose transport are podocytes (111), and these do not make up a large enough mass to 
explain changes observed. More likely, impairing the mobilization of fatty acids in renal tubule 
cells led to increased fatty acid storage and therefore decreased circulating NEFA, which could 
help to enhance both glucose utilization and insulin sensitivity in a variety of tissues such as 
adipose, skeletal muscle, and liver. Improved glycemia resulting from the impairment of fatty 
acid mobilization is also seen in global ATGL knockout mice, where complete loss of ATGL in all 
tissues severely impacts the use of fatty acids, and causes tissues to rely on glucose for energy 
metabolism. As predicted, however, the metabolic benefit of ATGL gene ablation in kidney did 
not last. 
By 16 weeks of age, we found KSAKO mice to be significantly more insulin resistant than WT 
mice. Fasted KSAKO mice had a much larger spike in blood glucose concentration when glucose 
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was injected i.p., which took longer to return to baseline, and they had a severely blunted 
hypoglycemic response to insulin injection. Thus, by 16 weeks, any benefit gained from an 
increase in glucose use is outweighed by the negative impact of ATGL loss in the kidney. Insulin 
resistance and CKD are often found together (7,11,97,112-115). However, our model clearly 
demonstrates that insulin resistance follows impairment in the ability to mobilize fatty acids in 
the kidney. The temporal nature of this finding is important for establishing a causal role for 
defective kidney lipid metabolism in systemic metabolic disease. Indeed, the demonstration 
that kidney dysfunction causes insulin resistance strongly supports a “two-way street” 
relationship between obesity and renal disease. Understanding the nature of the mechanisms 
that underlie this relationship will take considerable additional effort, although I have begun to 
investigate some of these. 
A prominent feature of CKD is the elevation of the inflammatory marker interleukin (IL)-6 
(116). I measured mRNA expression of the inflammatory markers Il-6, Il-1b and TNF-alpha in 
whole kidneys from 16-week old mice and found only Il-6 mRNA to be elevated by ATGL 
ablation. IL-6 is known to be involved in the recruitment, activation and proliferation of 
immunocytes, progressing the inflammatory response in kidney. IL-6 also exacerbates CKD-
associated co-morbidities by inhibiting the synthesis of adiponectin, an anti-atherogenic 
adipokine, in WAT (117). Atherogenesis is a serious complication of CKD and patients with CKD 
often die of CVD before succumbing to ESRD (118,119), per se. IL-6 is involved in the 
atherosclerotic process during the fibrous plaque development stage (120). We therefore also 
assessed whether fibrosis had been initiated in the kidney by measuring the expression of 
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fibrinogen in whole kidneys, and found it to be induced. Serum fibrinogen levels are a predictor 
of mortality in patients with CKD (121) in part due to the risk of cardiovascular events. 
The detrimental impact of altered lipid metabolism in the kidney as a result of Atgl ablation 
suggests that increasing renal lipolysis may be a mechanism to dissipate excess TAG stores and 
offer renoprotective effects, and hope for the treatment of kidney disease. The ablation of 
renal ATGL caused significant defects to whole body metabolism and, thus, the induction of 
renal lipolysis may prove beneficial in remedying these defects. Activation of PPARα by 
fenofibrate increases lipolysis and the oxidation of fatty acids (122). Fenofibrate treatment of 
rats has been shown to offer partial or full protection from renal lipotoxicity in diet-induced 
obesity models (123,124). Likewise, activation of AMPK, an activator of ATGL-mediated lipolysis 
(34), has been shown to reduce the severity of renal pathology associated with exposure to a 
high-fat diet (125). Dissipation of TAG in non-adipose tissues by treatment of rats with 
thiazolidinediones (TZDs) also ameliorates renal steatosis and lipotoxicity, and this effect was 
found to be dependent on the reduction in lipid loading, rather than treatment with TZDs per 
se (126). Similar effects may be achieved through tissue-specific increases in TAG hydrolysis. 
The continued study of renal lipolysis and potential activators of lipid enzymes involved in this 
process may prove to yield novel therapeutic options for the treatment of kidney disease and 





Defects in the ability to clear cellular lipids can result in lipid accumulation, promoting a 
lipotoxic environment. Cellular overstorage of lipids is a hallmark of the dysregulated obese 
state (15). A major complication of obesity is renal disease, which is associated with renal 
steatosis (21,22). The mechanisms mediating the declining kidney function associated with 
obesity are poorly understood, and recent literature suggests that kidney dysfunction alone can 
initiate or worsen metabolic syndrome, and increase the risk of cardiovascular disease (10-12). 
In association with obesity, kidney injury may result from lipid accumulation, diabetes, 
hypertension or a combination of several co-morbidities. To investigate the role of lipid 
accumulation alone in kidney pathology associated with obesity we created a model of renal 
lipid accumulation. 
The clearance of cellular lipid stores is mediated by lipolysis. The disruption of lipolysis 
by ablation of ATGL has been demonstrated to result in cellular lipid accumulation in most 
tissues (25,34). The renal tubule specific ablation of ATGL created in this thesis allows for the 
study of targeted disruption of lipolysis in the kidney.  
The KSAKO model created was a conditional knockout model under the control of Cre 
recombinase expression. Although this model was conditional under the expression of Cre, loss 
of Atgl was designed to begin at conception. KSAKO mice were essentially equal in terms of 
ratios of genotypes birthed, suggesting Mendelian genetics was not altered with Atgl ablation 
nor that this model was embryonic lethal. 
The resulting disruption to lipolysis in the kidney from Atgl loss is hypothesized to 
increase glucose utilization in the kidney in response to the inability to mobilize fatty acids for 
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beta-oxidation. As well, recent literature points to a possible role for the kidney in whole body 
glycemic control (10,11). Investigation of glycemic control was carried out by determining 
glucose and insulin tolerance testing in KSAKO and WT mice. The measurement of glycemic 
control at two time points allowed for the establishment of a timeline of pathology. As 
hypothesized, glucose sensitivity was increased in KSAKO mice compared to wildtype mice at 
the 9-week time point. The disruption in lipolysis likely increased utilization of glucose by the 
kidney, which increased blood glucose clearance. The essentially equal body weights observed 
in control and KSAKO mice at 9 weeks also suggested that excess lipids were not present at this 
time. However, we did not directly assess adipose tissue mass or organ weights at this time, 
and we may have seen opposing changes without a change in whole body mass. We further 
assessed glycemic control at 16 weeks of age to determine the effect of chronic Atgl ablation on 
glucose tolerance.  The targeted loss of Atgl for 16 weeks was associated with insulin resistance 
and glucose intolerance. The apparent reversal of glucose tolerance to intolerance from the 9 
week to the 16 week time point indicates a functional disruption occurring secondary to altered 
renal lipolysis. Glucose intolerance was hypothesized to be a result of renal steatosis, however 
neither this nor a change in body weight was detected at the 16 week time point. However, the 
induction of Hsl at 16 weeks implies that lipid accumulation likely occurred at an earlier time 
point and that lipotoxicity may have played a role in the development of insulin resistance prior 
to the 16 week time point. This is supported by the lack of evidence detected for the 
involvement of inflammation in the progression of glucose intolerance. Markers of 
inflammation were measured at 20 weeks of age and results suggested that inflammation was 
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only beginning to occur. Thus, it is unlikely that inflammation played a major role in the 
development of insulin resistance that was detected 4 weeks prior, at 16 weeks of age.  
At 20 weeks, it was also demonstrated that adipose tissue weights were decreased, and 
there was evidence of elevated adipocyte lipolysis. This indicates further evidence of 
dysregulated lipid handling in the body which may have played a role in altering glycemic 
control. Dysregulated WAT can result in elevated serum TAG, which we found evidence for, and 
likely contributed to the insulin resistance found at the 16 week time point. The dysregulation 
of WAT may have resulted from pathological kidney signalling to WAT at an earlier time point – 
for example, through changes in serum urinary proteins or miRNAs. It is not clear when the 
disruption to WAT occurred, and whether this occurred prior to measurement of insulin 
resistance at 16 weeks. Further investigation will be required to evaluate whether WAT 
dysregulation played a role in the development of insulin resistance in this model or whether 
pathological kidney changes alone were enough to interfere with whole body glucose disposal.  
A time line of events has been established to study the involvement of renal lipid 
metabolism in the pathogenesis of insulin resistance. Further investigation is required to 
elucidate the mechanism(s) involved in mediating insulin resistance in this model. The time line 
will be useful in identifying initiating factors that contribute to kidney pathology. The 
association of the KSAKO model with that of CKD may provide novel targets for the prevention 





ATGL has been shown to be an important mediator of lipid metabolism in WAT, liver and 
heart, with genetic ablation resulting in lipid accumulation. We demonstrate that renal tubule-
specific ATGL ablation results in a dysregulation to glucose metabolism, mediated through an 
as-of-yet undetermined mechanism. Our studies demonstrate the importance of renal ATGL in 
kidney homeostasis, and a possible role for renal lipolysis in initiating kidney damage. To 
provide definitive proof that lipid accumulation is a mediator of renal injury, it will be important 
to perform further studies in this KSAKO model.  
First, further work is needed to identify predicted effects of Atgl deficiency on lipid 
accumulation in specific cell types of the kidney. This renal tubule-specific model should show a 
reduction in ATGL levels in less than half of kidney cells, resulting in lipid accumulation only in 
these specific kidney ultra-structures. Identification and characterization of compensatory 
changes, such as an induction of HSL will also be important, as will characterization of timelines 
for the appearance of inflammatory markers and fibrosis. Examination of kidneys of older (>25 
week old) mice will also be of interest.  
Second, it will be important to investigate the timeline of extra-renal pathological changes 
in this KSAKO model, including what changes are associated with the early increase in insulin 
sensitivity that was seen at 9 weeks of age, and why this effect is reversed by 16 weeks of age. 
This work is comprised of many questions. When do adipose tissue depots begin to be 
dissipated? What factors link renal tubule-specific changes to dysregulated systemic 
metabolism? Are the changes progressive, and do they lead to greater severity of insulin 
resistance and eventual CVD with age? Evaluating renal pathology and systemic factors such as 
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blood lipids, glycemic control, and adipose tissue measures at 4, 8, 20, and 30 week time points 
will help to elucidate the progression of renal pathology with ATGL loss and its effect on global 
metabolism. 
Third, it will be interesting to characterize sex differences in the KSAKO model. I have 
performed preliminary studies on female KSAKO mice, suggesting that they have a radically 
different phenotype from male KSAKO mice, including improved insulin sensitivity and glycemic 
control at 16 weeks of age that is associated with a lower body weight gain from age 4 to 20 
weeks and possible increases in adipose tissue weights (Appendix). Whether differences in 
kidney and liver weights are also evident remains to be evaluated. 
The KSAKO model demonstrates the importance of renal lipolysis in regulating extra-renal 
effects such as WAT mass and systemic effects such as blood TAG concentration and glycemic 
control. The regulation of such wide-ranging effects likely requires the action of circulating 
endocrine factors. Possible mechanisms behind WAT dysregulation following disruption to renal 
lipolysis may involve toxic uremic proteins (93,94,96,97) and miRNA’s (98). Uremia is a common 
pathological consequence of CKD and is associated with the development of insulin resistance. 
Uremic toxins may be responsible for direct interruption of AKT signalling, promoting insulin 
resistance (99). Uremic toxins have also been shown to induce lipolysis in cultured adipocytes 
(96), which may promote lipid redistribution, as seen in our model. Direct measurement of 
serum creatinine and urea will be required to determine whether KSAKO mice develop uremia. 
Circulating miRNAs derived from the kidney may also mediate changes that were evident in 
KSAKO mice, including changes to adipose tissue depot masses, serum TAG concentrations, and 
development of impaired glycemic control. Dysregulated miRNAs have been found in to 
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mediate similar pathological changes to that which we saw in our model, including the 
redistribution of adipose tissue (92,101-103). Profiling of blood miRNAs in WT and KSAKO mice 
by next-generation sequencing will be important for identification of predicted and novel 
miRNAs that may mediate changes. The continued study of renal lipolysis and potential 
activators of lipid enzymes involved in this process may yield novel therapeutic options for the 




The topics in this thesis evaluated the suitability of renal ATGL ablation for the creation 
of a model of lipid accumulation in the kidney to study its role in the development in kidney 
dysfunction and associated co-morbidities including CVD and diabetes. I characterized ATGL 
and HSL expression and evaluated the nutritional regulation of lipolysis in murine whole 
kidneys. This first study allowed me to identify ATGL as an important modulator of lipid storage 
in the kidney, and was chosen as a suitable target for renal tubule specific genetic ablation. The 
renal tubule specific ablation of ATGL resulted in numerous metabolic changes including insulin 
resistance and adipose tissue redistribution. The work completed was meant to identify lipid 
accumulation in the kidney as an initial defect in kidney function leading to the progressive 
disruption of global metabolism.  Further work must be done on this model to elucidate the 
extent of cell specific lipid accumulation and kidney dysfunction. The characterization of KSAKO 
mice as a model for CKD would promote the factor of lipid accumulation as an early modulator 
in kidney disease and would positively benefit this field of research. Future projects should 
include the identification of signalling molecules involved in the renal-adipose axis to 
understand the cause and detriments of adipose redistribution, and characterization of the 
effect of renal lipid accumulation on cardiovascular measures, since this is an important co-
morbidity in patients with CKD. The completion of this work would allow for a more thorough 
understanding of the early defects responsible for the development and progression of kidney 
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APPENDIX – Additional Research Findings not presented in the main text 
Figures S1-S3 represent immunohistochemical detections in mouse 
kidney. (n=1) 
 
   
Figure S1: Kidney ATGL (green), Ppar-gamma (red), merge. 
 
   
Figure S2: Kindey ATGL (green), Leptin (red),  merge. 
 
   



































Figure S4: Kidney SREBP1c mRNA expression in female fasted mice at 20wks of age. (n=4-6) 
 
Figures S5-S11 represents the initial work completed on KSAKO 
female mice. 
























Figure S5: Body weights of female KSAKO mice over 20wks compared to WT and HET. 




























Figure S6: Tissue weights in female KSAKO mice at 20 wks of age. 
 





























Figure S7: Adipose tissue depot weights of female KSAKO mice at 20 wks of age. 
Female KSAKO mice demonstrate an opposite effect from KSAKO males. Adipose depots tend to 































Figure S8: Glucose tolerance test in female KSAKO mice at 9 wks of age. 

























Figure S9: Insulin tolerance test in female KSAKO mice at 9 wks of age. 
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Figure S10: Glucose tolerance test in female KSAKO mice at 16 wks of age. 


























Figure S11: Insulin tolerance test in female KSAKO mice at 16 wks of age.  
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Figures S12-S21 represent work completed on a 3day high fat diet 
study. 
The study consisted of female mice aged 16-20 wks divided into 4 study conditions. Either chow 
diet or high fat diet fed for 3 days and then either sacrificed or fasted for 16hr prior to sacrifice. 
 
Figure S12: Representative immunoblots of liver protein levels following a 16 hr fast in 16 wk 










Figure S13: Immunoblot of liver ATGL protein in female mice at 16 wks of age. 


































Figure S15:  Immunoblot of kidney ATGL protein. 








































































































































































Figure S22: Atgl mRNA expression in different brain regions. (ROB-rest of brain; HC-
hippocampus) 
 
Figure S23: Immunohistochemical detection of ATGL protein in SHSY-5Y cell line along neural 
dendrites. ATGL (red), NeuroTrace Stain (Life Technologies)(green), DAPI (blue) 
